<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:39:29Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10547278" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10547278</identifier>
        <datestamp>2023-10-04</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="jah38796" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10547278</article-id>
              <article-id pub-id-type="pmcid">PMC10547278</article-id>
              <article-id pub-id-type="pmc-uid">10547278</article-id>
              <article-id pub-id-type="pmid">37681568</article-id>
              <article-id pub-id-type="pmid">37681568</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.123.030071</article-id>
              <article-id pub-id-type="publisher-id">JAH38796</article-id>
              <article-id pub-id-type="other">JAHA/2023/030071</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Coronary Heart Disease</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Regression of Coronary Fatty Plaque and Risk of Cardiac Events According to Blood Pressure Status: Data From a Randomized Trial of Eicosapentaenoic Acid and Docosahexaenoic Acid in Patients With Coronary Artery Disease</article-title>
                <alt-title alt-title-type="right-running-head">Coronary Plaque Regression and Cardiac Events</alt-title>
                <alt-title alt-title-type="left-running-head">Welty et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah38796-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Welty</surname>
                    <given-names>Francine K.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0091-406X</contrib-id>
                  <xref rid="jah38796-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38796-note-0001" ref-type="author-notes">
                    <sup>*</sup>
                  </xref>
                  <address>
                    <email>francinewelty@gmail.com</email>
                  </address>
                </contrib>
                <contrib id="jah38796-cr-0002" contrib-type="author">
                  <name>
                    <surname>Hariri</surname>
                    <given-names>Essa</given-names>
                  </name>
                  <degrees>MD, MS</degrees>
                  <xref rid="jah38796-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="jah38796-note-0001" ref-type="author-notes">
                    <sup>*</sup>
                  </xref>
                </contrib>
                <contrib id="jah38796-cr-0003" contrib-type="author">
                  <name>
                    <surname>Asbeutah</surname>
                    <given-names>Abdul Aziz</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah38796-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38796-note-0001" ref-type="author-notes">
                    <sup>*</sup>
                  </xref>
                </contrib>
                <contrib id="jah38796-cr-0004" contrib-type="author">
                  <name>
                    <surname>Daher</surname>
                    <given-names>Ralph</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8880-2563</contrib-id>
                  <xref rid="jah38796-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah38796-cr-0005" contrib-type="author">
                  <name>
                    <surname>Amangurbanova</surname>
                    <given-names>Maral</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3799-3857</contrib-id>
                  <xref rid="jah38796-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah38796-cr-0006" contrib-type="author">
                  <name>
                    <surname>Chedid</surname>
                    <given-names>Georges</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5708-2954</contrib-id>
                  <xref rid="jah38796-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah38796-cr-0007" contrib-type="author">
                  <name>
                    <surname>Elajami</surname>
                    <given-names>Tarec K.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8019-2222</contrib-id>
                  <xref rid="jah38796-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah38796-cr-0008" contrib-type="author">
                  <name>
                    <surname>Alfaddagh</surname>
                    <given-names>Abdulhamied</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2801-7624</contrib-id>
                  <xref rid="jah38796-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah38796-cr-0009" contrib-type="author">
                  <name>
                    <surname>Malik</surname>
                    <given-names>Abdulaziz</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah38796-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="jah38796-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Division of Cardiology</named-content>
                <institution>Beth Israel Deaconess Medical Center</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jah38796-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>Cleveland Clinic Foundation</institution>
                <city>Cleveland</city>
                <named-content content-type="country-part">Ohio</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jah38796-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Gilbert and Rose‐Marie Chagoury School of Medicine</named-content>
                <institution>Lebanese American University</institution>
                <city>Byblos</city>
                <country country="LB">Lebanon</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Francine K. Welty, MD, PhD, Beth Israel Deaconess Medical Center, 330 Brookline, Avenue, Boston, MA 02215.<break/>
Email: <email>francinewelty@gmail.com</email>
<break/>
</corresp>
                <fn fn-type="equal" id="jah38796-note-0001">
                  <label>*</label>
                  <p>F. K. Welty, E. Hariri and A. A. Asbeutah contributed equally.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>08</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>19</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <volume>12</volume>
              <issue seq="120">18</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v12.18</issue-id>
              <elocation-id>e030071</elocation-id>
              <history>
                <date date-type="received">
                  <day>16</day>
                  <month>3</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>10</day>
                  <month>8</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <!--Copyright &#x000a9; 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell-->
                <copyright-statement content-type="article-copyright">© 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-12-e030071.pdf"/>
              <abstract>
                <sec id="jah38796-sec-0001">
                  <title>Background</title>
                  <p>Residual risk of cardiovascular events and plaque progression remains despite reduction in low‐density lipoprotein cholesterol. Factors contributing to residual risk remain unclear. The authors examined the role of eicosapentaenoic acid and docosahexaenoic acid in coronary plaque regression and its predictors.</p>
                </sec>
                <sec id="jah38796-sec-0002">
                  <title>Methods and Results</title>
                  <p>A total of 240 patients with stable coronary artery disease were randomized to eicosapentaenoic acid plus docosahexaenoic acid (3.36 g/d) or none for 30 months. Patients were stratified by regression or progression of coronary fatty plaque measured by coronary computed tomographic angiography. Cardiac events were ascertained. The mean±SD age was 63.0±7.7 years, mean low‐density lipoprotein cholesterol level was &lt;2.07 mmol/L, and median triglyceride level was &lt;1.38 mmol/L. Regressors had a 14.9% reduction in triglycerides that correlated with fatty plaque regression (<italic toggle="no">r</italic>=0.135; <italic toggle="no">P</italic>=0.036). Compared with regressors, progressors had higher cardiac events (5% vs 22.3%, respectively; <italic toggle="no">P</italic>&lt;0.001) and a 2.89‐fold increased risk of cardiac events (95% CI, 1.1–8.0; <italic toggle="no">P</italic>=0.034). Baseline non–high‐density lipoprotein cholesterol level &lt;2.59 mmol/L (100 mg/dL) and systolic blood pressure &lt;125 mm Hg were significant independent predictors of fatty plaque regression. Normotensive patients taking eicosapentaenoic acid plus docosahexaenoic acid had regression of noncalcified coronary plaque that correlated with triglyceride reduction (<italic toggle="no">r</italic>=0.35; <italic toggle="no">P</italic>=0.034) and a significant decrease in neutrophil/lymphocyte ratio. In contrast, hypertensive patients had no change in noncalcified coronary plaque or neutrophil/lymphocyte ratio.</p>
                </sec>
                <sec id="jah38796-sec-0003">
                  <title>Conclusions</title>
                  <p>Triglyceride reduction, systolic blood pressure &lt;125 mm Hg, and non–high‐density lipoprotein cholesterol &lt;2.59 mmol/L were associated with coronary plaque regression and reduced cardiac events. Normotensive patients had greater benefit than hypertensive patients potentially due to lower levels of inflammation. Future studies should examine the role of inflammation in plaque regression.</p>
                </sec>
                <sec id="jah38796-sec-0004">
                  <title>Registration</title>
                  <p>URL: <ext-link xlink:href="https://www.clinicaltrials.gov" ext-link-type="uri">https://www.clinicaltrials.gov</ext-link>; Unique identifier: NCT01624727.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jah38796-kwd-0001">cardiovascular events</kwd>
                <kwd id="jah38796-kwd-0002">coronary computed tomographic angiography</kwd>
                <kwd id="jah38796-kwd-0003">coronary plaque regression</kwd>
                <kwd id="jah38796-kwd-0004">eicosapentaenoic acid</kwd>
                <kwd id="jah38796-kwd-0005">triglyceride</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Clinical Studies</kwd>
                <kwd>Inflammation</kwd>
                <kwd>Lipids and Cholesterol</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>National Institutes of Health Specialized Center of Clinically Oriented Research</funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>Harvard Clinical and Translational Science Center Award (NIH</funding-source>
                  <award-id>UL1 TR001102</award-id>
                  <award-id>P50HL083813)</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="4"/>
                <table-count count="10"/>
                <page-count count="17"/>
                <word-count count="8073"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>19 September 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.4 mode:remove_FC converted:19.09.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <fn-group id="jah38796-ntgp-0001">
                <fn id="jah38796-note-0002">
                  <p>This work was presented in part at the American Heart Association Scientific Sessions, November 5–7, 2022.</p>
                </fn>
                <fn id="jah38796-note-0003">
                  <p>This article was sent to Yen‐Hung Lin, MD, PhD, Associate Editor, for review by expert referees, editorial decision, and final disposition.</p>
                </fn>
                <fn id="jah38796-note-0004">
                  <p>For Sources of Funding and Disclosures, see page 15.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah38796-body-0001">
            <def-list list-content="abbreviations" id="jah38796-lp-0001">
              <title>Nonstandard Abbreviations and Acronyms</title>
              <def-item>
                <term id="jah38796-li-0001">DHA</term>
                <def id="jah38796-li-0002">
                  <p>docosahexaenoic acid</p>
                </def>
              </def-item>
              <def-item>
                <term id="jah38796-li-0003">EPA</term>
                <def id="jah38796-li-0004">
                  <p>eicosapentaenoic acid</p>
                </def>
              </def-item>
              <def-item>
                <term id="jah38796-li-0005">HEARTS</term>
                <def id="jah38796-li-0006">
                  <p>Slowing Heart Disease With Lifestyle and Omega‐3 Fatty Acids</p>
                </def>
              </def-item>
              <def-item>
                <term id="jah38796-li-0007">HU</term>
                <def id="jah38796-li-0008">
                  <p>hounsfield units</p>
                </def>
              </def-item>
              <def-item>
                <term id="jah38796-li-0009">NLR</term>
                <def id="jah38796-li-0010">
                  <p>neutrophil lymphocyte ratio</p>
                </def>
              </def-item>
              <def-item>
                <term id="jah38796-li-0011">SPRINT</term>
                <def id="jah38796-li-0012">
                  <p>Systolic Blood Pressure Intervention Trial</p>
                </def>
              </def-item>
              <def-item>
                <term id="jah38796-li-0013">WHHL</term>
                <def id="jah38796-li-0014">
                  <p>Watanabe heritable hyperlipidemic</p>
                </def>
              </def-item>
            </def-list>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah38796-blkfxd-0001">
                <caption>
                  <title>Clinical Perspective</title>
                </caption>
                <sec id="jah38796-sec-0007">
                  <title>What Is New?</title>
                  <p>
                    <list list-type="bullet" id="jah38796-list-0001">
                      <list-item id="jah38796-li-0015">
                        <p>Predictors of regression of coronary fatty plaque include baseline levels of non–high‐density lipoprotein cholesterol &lt;2.59 mmol/L and systolic blood pressure &lt;125 mm Hg and reduction in triglyceride level over 30 months in patients with stable coronary artery disease with normal triglyceride levels on statin therapy randomized to high‐dose eicosapentaenoic acid and docosahexaenoic acid.</p>
                      </list-item>
                      <list-item id="jah38796-li-0016">
                        <p>Regressors had a 4‐fold lower risk of major adverse cardiovascular events.</p>
                      </list-item>
                      <list-item id="jah38796-li-0017">
                        <p>Normotensive patients taking eicosapentaenoic acid and docosahexaenoic acid had regression of noncalcified coronary plaque and reduction of triglyceride level and neutrophil/lymphocyte ratio compared with control, whereas hypertensive patients had no difference.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
                <sec id="jah38796-sec-0008">
                  <title>What Are the Clinical Implications?</title>
                  <p>
                    <list list-type="bullet" id="jah38796-list-0002">
                      <list-item id="jah38796-li-0018">
                        <p>The study supports the importance of maintaining a systolic blood pressure &lt;125 mm Hg and non–high‐density lipoprotein cholesterol &lt;2.59 mmol/L to reduce residual cardiovascular risk through coronary plaque regression.</p>
                      </list-item>
                      <list-item id="jah38796-li-0019">
                        <p>The association of triglyceride lowering with eicosapentaenoic acid plus docosahexaenoic acid and regression of coronary fatty plaque supports use of omega‐3 fatty acids to reduce residual cardiovascular risk in patients with coronary artery disease with normal triglyceride levels on statin therapy.</p>
                      </list-item>
                      <list-item id="jah38796-li-0020">
                        <p>The study highlights the importance of maintaining optimal triglyceride levels, non–high‐density lipoprotein cholesterol levels and systolic blood pressure, in addition to guideline‐recommended low‐density lipoprotein cholesterol levels, to regress coronary fatty plaque and thus optimize secondary prevention of cardiac events.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
            </p>
            <p>Low‐density lipoprotein cholesterol (LDL‐C) reduction has been the primary target to reduce the risk of cardiovascular disease (CVD) morbidity and mortality. However, despite maximal LDL‐C reduction on statin therapy, significant residual risk for cardiovascular events remains,<xref rid="jah38796-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="jah38796-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="jah38796-bib-0003" ref-type="bibr"><sup>3</sup></xref> and coronary artery disease (CAD) remains the leading cause of death in industrialized countries. Prior studies with coronary computed tomographic angiography (CCTA) and intravascular ultrasound have shown that progression of noncalcified coronary plaque is associated with higher rates of cardiovascular events,<xref rid="jah38796-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="jah38796-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="jah38796-bib-0006" ref-type="bibr"><sup>6</sup></xref> and regression of plaque is associated with fewer events.<xref rid="jah38796-bib-0003" ref-type="bibr"><sup>3</sup></xref> Identification of potential mechanisms contributing to cardiovascular events and plaque progression is important because it may allow modification and thus reduction of residual risk.</p>
            <p>Omega‐3 fatty acids are polyunsaturated fatty acids required in the diet to provide the very long‐chain eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for metabolic structure and function. We previously reported that achieving an omega‐3 fatty acid index ≥4% with 3.36 g daily of EPA plus DHA added to statin treatment prevented progression of noncalcified plaque over 30 months and that an index of 8.4% was associated with regression of noncalcified plaque in nondiabetic patients.<xref rid="jah38796-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jah38796-bib-0008" ref-type="bibr"><sup>8</sup></xref> Fatty plaque is a lipid‐rich plaque that is vulnerable to rupture, leading to thrombosis and acute coronary syndromes.<xref rid="jah38796-bib-0009" ref-type="bibr"><sup>9</sup></xref> Therefore, we undertook a strategy to determine predictors of regression of fatty plaque to provide insight into factors that may affect residual risk on statin therapy. We stratified patients by regression or progression of fatty plaque using CCTA to measure plaque volumes in our 30‐month randomized trial of EPA+DHA in patients with CAD taking statin therapy. Cardiac events were assessed. CCTA is noninvasive and allows for examination of all coronary arteries, in contrast to intravascular ultrasound imaging, which generally examines only a culprit artery and is invasive with inherent risks. CCTA has been validated to detect progression of coronary plaque volume<xref rid="jah38796-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="jah38796-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="jah38796-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="jah38796-bib-0013" ref-type="bibr"><sup>13</sup></xref> and has shown that statin therapy attenuates progression of coronary plaque.<xref rid="jah38796-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="jah38796-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="jah38796-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="jah38796-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="jah38796-bib-0018" ref-type="bibr"><sup>18</sup></xref>
</p>
            <sec sec-type="methods" id="jah38796-sec-0009">
              <title>METHODS</title>
              <sec id="jah38796-sec-0010">
                <title>Study Design</title>
                <p>The HEARTS (Slowing Heart Disease With Lifestyle and Omega‐3 Fatty Acids) trial is a randomized clinical trial conducted at Beth Israel Deaconess Medical Center (BIDMC), Boston, MA. The BIDMC's institutional review board approved the protocol, and all patients signed informed consent. The effect of EPA+DHA on progression of coronary noncalcified plaque at 30‐month follow‐up is the primary end point and has been reported.<xref rid="jah38796-bib-0019" ref-type="bibr"><sup>19</sup></xref> Prespecified secondary end points include prevention of progression of albuminuria by EPA and DHA in diabetic patients<xref rid="jah38796-bib-0020" ref-type="bibr"><sup>20</sup></xref>; effect of EPA and DHA on physical function, exercise, and joint replacement<xref rid="jah38796-bib-0021" ref-type="bibr"><sup>21</sup></xref>; diastolic blood pressure (BP) as a predictor of noncalcified coronary plaque volume<xref rid="jah38796-bib-0022" ref-type="bibr"><sup>22</sup></xref>; and effect of EPA and DHA on cognitive function.<xref rid="jah38796-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="jah38796-bib-0024" ref-type="bibr"><sup>24</sup></xref> The data that support the findings of this study are available from the corresponding author upon reasonable request. The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) cohort reporting guidelines were used.</p>
              </sec>
              <sec id="jah38796-sec-0011">
                <title>Participants and Study Intervention</title>
                <p>Participating patients were aged 37 to 80 years and had stable CAD as previously defined.<xref rid="jah38796-bib-0019" ref-type="bibr"><sup>19</sup></xref> Patients were randomized to 1.86 g EPA and 1.5 g DHA or no EPA and DHA (control) for 30 months. All patients were recommended statin and aspirin and were instructed not to take over‐the‐counter omega‐3 fatty acid supplementation.</p>
              </sec>
              <sec id="jah38796-sec-0012">
                <title>Data Collection</title>
                <p>History, physical examination, BP, height, weight, and waist measurement were obtained at baseline and every 6 months. After a 12‐hour fast, blood samples were obtained, and biochemical and lipid levels were measured at Quest Diagnostics (Cambridge, MA). High‐sensitivity CRP (C‐reactive protein), plasma EPA, DHA, and total fatty acids and small dense LDL‐C were measured as previously described.<xref rid="jah38796-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jah38796-bib-0025" ref-type="bibr"><sup>25</sup></xref> The plasma omega‐3 fatty acid index was the percentage that EPA+DHA comprised total fatty acids.</p>
              </sec>
              <sec id="jah38796-sec-0013">
                <title>Cardiac Events</title>
                <p>Cardiac events were reported every 3 months until the final visit at 30 months. Cardiac events included unstable angina, myocardial infarction (MI), percutaneous coronary intervention, and coronary artery bypass grafting. Unstable angina was defined as onset of angina at rest. MI was defined according to the Third Universal Definition of Myocardial Infarction.<xref rid="jah38796-bib-0026" ref-type="bibr"><sup>26</sup></xref> Events were documented through review of medical records. Data were analyzed as time‐to‐first event.</p>
              </sec>
              <sec id="jah38796-sec-0014">
                <title>Image Acquisition, Reconstruction, and Coronary Plaque Analysis</title>
                <p>A 320‐row detector scanner (Aquilion ONE, Toshiba Medical Systems) with prospective ECG gating was used for imaging at BIDMC. The protocol for plaque identification and quantification has been previously published.<xref rid="jah38796-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="jah38796-bib-0028" ref-type="bibr"><sup>28</sup></xref> Representative images of coronary artery segments demonstrating progression [A] and regression [B] of coronary plaque over 30 months are shown in the eFigure in Supplement 2 of Reference [<xref rid="jah38796-bib-0028" ref-type="bibr">28</xref>]. Three‐dimensional reconstruction of CCTA images for coronary segment plaque volume analysis was performed with semiautomated software (SUREPlaque, version 6.3.2; Vital Images).<xref rid="jah38796-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="jah38796-bib-0029" ref-type="bibr"><sup>29</sup></xref>, <xref rid="jah38796-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="jah38796-bib-0031" ref-type="bibr"><sup>31</sup></xref> To exclude calcium‐bloom artifact, segments with prior revascularization or significant calcification were excluded. To ensure measurement of the same segment at 30‐month follow‐up, branches or focal calcification served as fiducial markers. Two readers blinded to treatment allocation performed the plaque analyses independently. Hounsfield unit (HU) densities were used to classify plaque, with fatty plaque being −100 to 49 HU, fibrous plaque, 50 to 150 HU, and calcified plaque &gt;150 HU. Noncalcified plaque was the sum of fatty and fibrous plaque. Indexed plaque volume was defined as plaque volume (mm<sup>3</sup>) divided by artery segment length (mm). The HEARTS trial was powered to detect a difference of 4% change in coronary plaque volume at 30 months using CCTA. Therefore, our cut point for separating those with progression versus regression of plaque took the 4% margin into account. Plaque regression was defined as ≤−2% reduction in fatty plaque volume and progression as &gt;+2% increase in fatty plaque volume. A third group classified as “no change” included those with &lt;−2% reduction and up to +2% plaque progression.</p>
              </sec>
              <sec id="jah38796-sec-0015">
                <title>Statistical Analysis</title>
                <p>Patients were grouped according to change in coronary fatty plaque for the total group of patients regardless of treatment assignment. Categorical variables were expressed as counts and percentages. Normality tests were conducted using the Shapiro–Wilk test. Continuous variables were reported as the mean and SD for normally distributed variables or median and interquartile range [IQR] for nonnormally distributed variables. Continuous variables were compared using 2‐tailed paired <italic toggle="yes">t</italic> tests and unpaired <italic toggle="yes">t</italic> tests at 30 months compared with baseline for normally distributed variables and Wilcoxon signed rank test and the Mann–Whitney <italic toggle="yes">U</italic> test for nonnormally distributed variables. Spearman correlation coefficients were determined. Hazard ratio (HRs) and 95% CIs for the association between plaque change and cardiovascular events were estimated using Cox proportional‐hazard regression. Freedom from cardiovascular events in progressors versus regressors was graphed with a Kaplan–Meier plot. We then examined baseline variables predicting arithmetic change in fatty plaque from baseline to 30 months. The correlation coefficient, <italic toggle="yes">r</italic>, was used to measure the correlation between each continuous variable and arithmetic change in fatty plaque. The following discrete variables were also used to determine in univariate analyses whether they were associated with change in fatty plaque from baseline to 30 months: randomized treatment, sex, race, diabetes, and hypertension. Analysis of variance was used to assess the effect of each discrete variable on arithmetic change in fatty plaque. Analysis of covariance was used for multivariable‐adjusted regression analyses. The final regression model was built using a stepwise backward procedure for variable selection with criterion <italic toggle="yes">P</italic>&lt;0.05 for inclusion. A 2‐sided <italic toggle="yes">P</italic> value ≤0.05 was considered statistically significant. Data analyses were performed using SPSS 20.0 (IBM) and R programming version 4.2.2 (R Project for Statistical Computing).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah38796-sec-0016">
              <title>RESULTS</title>
              <sec id="jah38796-sec-0017">
                <title>Baseline Characteristics</title>
                <p>A total of 285 patients with stable CAD were randomized to EPA+DHA (n=143) or none (n=142). Of these, 126 in the EPA+DHA group and 114 in the control group had paired CCTA scans at baseline and 30‐month follow‐up and were included in the current analysis. The mean age was 63.0 years (SD, 7.7 years), and 15% were women. Table <xref rid="jah38796-tbl-0001" ref-type="table">1</xref> describes baseline characteristics stratified by regression, no change, or progression of coronary fatty plaque at 30 months. Compared with the regressor group, progressors were significantly more likely to be taking a statin (<italic toggle="yes">P</italic>=0.04) and have higher levels of white blood cell (WBC) and neutrophil counts (<italic toggle="yes">P</italic>=0.019 and <italic toggle="yes">P</italic>=0.037, respectively) at baseline. Of note, median high‐sensitivity CRP values were ≤0.9 mg/L in each group.</p>
                <table-wrap position="float" id="jah38796-tbl-0001" content-type="Table">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline Characteristics in the Regressor, No Change, and Progressor Groups</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1"/>
                        <th align="left" rowspan="1" colspan="1">Regressors ≤−2% n=100</th>
                        <th align="left" rowspan="1" colspan="1">No change &gt;−2% to +2% n=19</th>
                        <th align="left" rowspan="1" colspan="1">Progressors &gt;+2% n=121</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value<xref rid="jah38796-note-0006" ref-type="table-fn">*</xref>
</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Demographic characteristics</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, mean (SD), y</td>
                        <td align="left" rowspan="1" colspan="1">62.8 (8.0)</td>
                        <td align="left" rowspan="1" colspan="1">62.7 (6.7)</td>
                        <td align="left" rowspan="1" colspan="1">63.2 (7.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.70</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Men, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">84 (84.0)</td>
                        <td align="left" rowspan="1" colspan="1">15 (78.9)</td>
                        <td align="left" rowspan="1" colspan="1">105 (86.8)</td>
                        <td align="left" rowspan="1" colspan="1">0.63</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Inclusion criteria (may have &gt;1), n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of MI</td>
                        <td align="left" rowspan="1" colspan="1">51 (51.0)</td>
                        <td align="left" rowspan="1" colspan="1">9 (47.4)</td>
                        <td align="left" rowspan="1" colspan="1">52 (43.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.49</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Percutaneous coronary intervention</td>
                        <td align="left" rowspan="1" colspan="1">64 (64.0)</td>
                        <td align="left" rowspan="1" colspan="1">10 (52.6)</td>
                        <td align="left" rowspan="1" colspan="1">76 (62.8)</td>
                        <td align="left" rowspan="1" colspan="1">0.64</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Coronary artery bypass graft</td>
                        <td align="left" rowspan="1" colspan="1">27 (27.0)</td>
                        <td align="left" rowspan="1" colspan="1">3 (15.8)</td>
                        <td align="left" rowspan="1" colspan="1">29 (24.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.57</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Cardiovascular risk factors, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td>
                        <td align="left" rowspan="1" colspan="1">84 (84.0)</td>
                        <td align="left" rowspan="1" colspan="1">14 (73.7)</td>
                        <td align="left" rowspan="1" colspan="1">102 (84.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.50</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes</td>
                        <td align="left" rowspan="1" colspan="1">31 (31.0)</td>
                        <td align="left" rowspan="1" colspan="1">6 (31.6)</td>
                        <td align="left" rowspan="1" colspan="1">31 (25.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.64</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Anthropometrics and BP, mean (SD)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Weight, kg</td>
                        <td align="left" rowspan="1" colspan="1">91.5 (12.9)</td>
                        <td align="left" rowspan="1" colspan="1">89.4 (14.0)</td>
                        <td align="left" rowspan="1" colspan="1">91.8 (14.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.87</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">30.4 (3.5)</td>
                        <td align="left" rowspan="1" colspan="1">29.8 (3.2)</td>
                        <td align="left" rowspan="1" colspan="1">31.0 (3.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.20</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Waist circumference, cm</td>
                        <td align="left" rowspan="1" colspan="1">105.7 (10.0)</td>
                        <td align="left" rowspan="1" colspan="1">102.8 (8.5)</td>
                        <td align="left" rowspan="1" colspan="1">107.9 (10.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.22</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic BP, mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">122.9 (12.6)</td>
                        <td align="left" rowspan="1" colspan="1">122.2 (16.3)</td>
                        <td align="left" rowspan="1" colspan="1">125.8 (15.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.13</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diastolic BP, mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">73.1 (9.4)</td>
                        <td align="left" rowspan="1" colspan="1">70.0 (8.1)</td>
                        <td align="left" rowspan="1" colspan="1">73.9 (10.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.58</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Medications, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Statin</td>
                        <td align="left" rowspan="1" colspan="1">91 (91)</td>
                        <td align="left" rowspan="1" colspan="1">19 (100)</td>
                        <td align="left" rowspan="1" colspan="1">118 (97.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.04</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin</td>
                        <td align="left" rowspan="1" colspan="1">94 (94)</td>
                        <td align="left" rowspan="1" colspan="1">19 (100)</td>
                        <td align="left" rowspan="1" colspan="1">118 (97.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.31</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ACEI</td>
                        <td align="left" rowspan="1" colspan="1">54 (54)</td>
                        <td align="left" rowspan="1" colspan="1">8 (42.1)</td>
                        <td align="left" rowspan="1" colspan="1">69 (57.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.47</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ARB</td>
                        <td align="left" rowspan="1" colspan="1">14 (14)</td>
                        <td align="left" rowspan="1" colspan="1">4 (21.1)</td>
                        <td align="left" rowspan="1" colspan="1">28 (23.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.22</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hydrochlorothiazide</td>
                        <td align="left" rowspan="1" colspan="1">23 (23)</td>
                        <td align="left" rowspan="1" colspan="1">4 (21.1)</td>
                        <td align="left" rowspan="1" colspan="1">18 (14.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.30</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Furosemide</td>
                        <td align="left" rowspan="1" colspan="1">7 (7)</td>
                        <td align="left" rowspan="1" colspan="1">1 (5.3)</td>
                        <td align="left" rowspan="1" colspan="1">11 (9.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.77</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Calcium channel blocker</td>
                        <td align="left" rowspan="1" colspan="1">30 (30)</td>
                        <td align="left" rowspan="1" colspan="1">1 (5.3)</td>
                        <td align="left" rowspan="1" colspan="1">27 (22.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.055</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">β‐Blocker</td>
                        <td align="left" rowspan="1" colspan="1">76 (76)</td>
                        <td align="left" rowspan="1" colspan="1">13 (68.4)</td>
                        <td align="left" rowspan="1" colspan="1">84 (69.4)</td>
                        <td align="left" rowspan="1" colspan="1">0.52</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">High‐sensitivity CRP and CBC count</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">High‐sensitivity CRP, median [IQR], mg/L</td>
                        <td align="left" rowspan="1" colspan="1">0.9 [0.4–2.4]</td>
                        <td align="left" rowspan="1" colspan="1">0.6 [0.3–1.1]</td>
                        <td align="left" rowspan="1" colspan="1">0.8 [0.4–2.3]</td>
                        <td align="left" rowspan="1" colspan="1">0.42</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">WBC count, mean (SD), 10<sup>9</sup> cells/L</td>
                        <td align="left" rowspan="1" colspan="1">6.4 (1.4)</td>
                        <td align="left" rowspan="1" colspan="1">6.1 (1.5)</td>
                        <td align="left" rowspan="1" colspan="1">7.0 (2.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.019</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Monocytes, mean (SD), cells/μL</td>
                        <td align="left" rowspan="1" colspan="1">510 (153)</td>
                        <td align="left" rowspan="1" colspan="1">522 (217)</td>
                        <td align="left" rowspan="1" colspan="1">545 (169)</td>
                        <td align="left" rowspan="1" colspan="1">0.11</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Neutrophils, mean (SD), cells/μL</td>
                        <td align="left" rowspan="1" colspan="1">3976 (1243)</td>
                        <td align="left" rowspan="1" colspan="1">3624 (1284)</td>
                        <td align="left" rowspan="1" colspan="1">4384 (1574)</td>
                        <td align="left" rowspan="1" colspan="1">0.037</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lymphocytes, mean (SD), cells/μL</td>
                        <td align="left" rowspan="1" colspan="1">1656 (540)</td>
                        <td align="left" rowspan="1" colspan="1">1707 (546)</td>
                        <td align="left" rowspan="1" colspan="1">1849 (1915)</td>
                        <td align="left" rowspan="1" colspan="1">0.33</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Platelets, mean (SD), cells/μL</td>
                        <td align="left" rowspan="1" colspan="1">191 (46)</td>
                        <td align="left" rowspan="1" colspan="1">200 (44)</td>
                        <td align="left" rowspan="1" colspan="1">190 (54)</td>
                        <td align="left" rowspan="1" colspan="1">0.91</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Lipids, mean (SD), except triglyceride, non–HDL‐C, small dense LDL‐C, and remnant cholesterol, which are median [IQR]</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total cholesterol, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">3.88 (0.92)</td>
                        <td align="left" rowspan="1" colspan="1">3.88 (0.80)</td>
                        <td align="left" rowspan="1" colspan="1">3.99 (0.96)</td>
                        <td align="left" rowspan="1" colspan="1">0.39</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">150.1±35.4</td>
                        <td align="left" rowspan="1" colspan="1">150.1±31.0</td>
                        <td align="left" rowspan="1" colspan="1">154.3±37.1</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Triglycerides, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">1.36 [1.01–1.90]</td>
                        <td align="left" rowspan="1" colspan="1">1.03 [0.82–1.58]</td>
                        <td align="left" rowspan="1" colspan="1">1.36 [0.89–2.00]</td>
                        <td align="left" rowspan="1" colspan="1">0.94</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">120.5 [89–168]</td>
                        <td align="left" rowspan="1" colspan="1">91 [73–140]</td>
                        <td align="left" rowspan="1" colspan="1">121 [79–177]</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">HDL‐C, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">1.22 (0.43)</td>
                        <td align="left" rowspan="1" colspan="1">1.29 (0.39)</td>
                        <td align="left" rowspan="1" colspan="1">1.21 (0.32)</td>
                        <td align="left" rowspan="1" colspan="1">0.75</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">47.2±16.8</td>
                        <td align="left" rowspan="1" colspan="1">49.7±14.9</td>
                        <td align="left" rowspan="1" colspan="1">46.6±12.4</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL‐C, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">1.96 (0.63)</td>
                        <td align="left" rowspan="1" colspan="1">2.01 (0.61)</td>
                        <td align="left" rowspan="1" colspan="1">2.06 (0.77)</td>
                        <td align="left" rowspan="1" colspan="1">0.29</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">75.8±24.5</td>
                        <td align="left" rowspan="1" colspan="1">77.9±23.6</td>
                        <td align="left" rowspan="1" colspan="1">79.8±29.8</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non–HDL‐C, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">2.41 [1.99–3.00]</td>
                        <td align="left" rowspan="1" colspan="1">2.52 [2.12–2.90]</td>
                        <td align="left" rowspan="1" colspan="1">2.52 [2.17–3.08]</td>
                        <td align="left" rowspan="1" colspan="1">0.22</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">93.0 [77.0–116.0]</td>
                        <td align="left" rowspan="1" colspan="1">97.5 [82.0–112.0]</td>
                        <td align="left" rowspan="1" colspan="1">97.5 [84.0–119.0]</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Small dense LDL‐C, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">0.54 [0.29–0.82]</td>
                        <td align="left" rowspan="1" colspan="1">0.57 [0.30–0.80]</td>
                        <td align="left" rowspan="1" colspan="1">0.53 [0.32–0.86]</td>
                        <td align="left" rowspan="1" colspan="1">0.16</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">20.7 [11.4–31.7]</td>
                        <td align="left" rowspan="1" colspan="1">21.9 [11.7–31.0]</td>
                        <td align="left" rowspan="1" colspan="1">20.5 [12.5–33.1]</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Remnant cholesterol, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">0.62 [0.47–0.87]</td>
                        <td align="left" rowspan="1" colspan="1">0.47 [0.39–0.72]</td>
                        <td align="left" rowspan="1" colspan="1">0.62 [0.41–0.91]</td>
                        <td align="left" rowspan="1" colspan="1">0.95</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">24.0 [18.0–33.5]</td>
                        <td align="left" rowspan="1" colspan="1">18.0 [15.0–28.0]</td>
                        <td align="left" rowspan="1" colspan="1">24.0 [16.0–35.0]</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Biochemical profile, mean (SD), except omega‐3 fatty acid index and albumin‐creatinine ratio, which are median [IQR]</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Glucose, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">5.9 (1.8)</td>
                        <td align="left" rowspan="1" colspan="1">6.2 (2.2)</td>
                        <td align="left" rowspan="1" colspan="1">5.8 (1.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.86</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">105.9±32.1</td>
                        <td align="left" rowspan="1" colspan="1">111.7±39.2</td>
                        <td align="left" rowspan="1" colspan="1">105.2±29.5</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hemoglobin A1c, %</td>
                        <td align="left" rowspan="1" colspan="1">6.1 (0.9)</td>
                        <td align="left" rowspan="1" colspan="1">6.2 (1.3)</td>
                        <td align="left" rowspan="1" colspan="1">6.2 (0.8)</td>
                        <td align="left" rowspan="1" colspan="1">0.72</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Estimated creatinine clearance, mL/minute</td>
                        <td align="left" rowspan="1" colspan="1">100.2 (21.4)</td>
                        <td align="left" rowspan="1" colspan="1">98.5 (24.0)</td>
                        <td align="left" rowspan="1" colspan="1">103.4 (31.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.40</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Omega‐3 fatty acid index %, median [IQR]</td>
                        <td align="left" rowspan="1" colspan="1">3.3 [2.6–4.4]</td>
                        <td align="left" rowspan="1" colspan="1">3.1 [2.46–3.6]</td>
                        <td align="left" rowspan="1" colspan="1">3.3 [2.5–4.3]</td>
                        <td align="left" rowspan="1" colspan="1">0.26</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Albumin‐creatinine ratio, μg/mg creatinine, median [IQR]</td>
                        <td align="left" rowspan="1" colspan="1">5.0 [2.5–11.5]</td>
                        <td align="left" rowspan="1" colspan="1">3.5 [1.9–4.0]</td>
                        <td align="left" rowspan="1" colspan="1">4.4 [2.9–9.0]</td>
                        <td align="left" rowspan="1" colspan="1">0.60</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38796-ntgp-0002">
                    <fn id="jah38796-note-0005">
                      <p>SI conversion factors: to convert cholesterol levels to mg/dL, divide by 0.0259; triglyceride level to mg/dL, divide by 0.0113; and glucose level to mg/dL, divide by 0.0555. ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CBC, complete blood count; CRP, C‐reactive protein; HDL‐C, high‐density lipoprotein cholesterol; IQR, interquartile range; LDL‐C, low‐density lipoprotein cholesterol; MI, myocardial infarction; WBC, white blood cell.</p>
                    </fn>
                    <fn id="jah38796-note-0006">
                      <label>*</label>
                      <p><italic toggle="yes">P</italic> value compares regressors with progressors.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah38796-sec-0018">
                <title>Regression and Progression of Coronary Plaque</title>
                <p>Figure <xref rid="jah38796-fig-0001" ref-type="fig">1</xref> (data in Table <xref rid="jah38796-tbl-0002" ref-type="table">2</xref>) reports that regressors had significant regression of fatty (median, −12.5% [IQR, −20.6 to −7.1], <italic toggle="yes">P</italic>&lt;0.001), fibrous (−8.7% [IQR, −19.5 to 1.4], <italic toggle="yes">P</italic>&lt;0.001), noncalcified (−9.5% [IQR, −19.3 to −4.0], <italic toggle="yes">P</italic>&lt;0.001), and total coronary (−3.0% [IQR, −13.7 to 6.3], <italic toggle="yes">P</italic>&lt;0.001) plaque, whereas progressors had significant progression of fatty (16% [IQR, 8.0–32.6], <italic toggle="yes">P</italic>&lt;0.001), fibrous (14.5% [IQR, 1.5–26.4], <italic toggle="yes">P</italic>&lt;0.001), noncalcified (15.1% [IQR, 5.0–27.2], <italic toggle="yes">P</italic>&lt;0.001), calcified (40.8% [IQR, 0.8–118.4], <italic toggle="yes">P</italic>&lt;0.001), and total coronary (19.0% [IQR, 7.9–33.8], <italic toggle="yes">P</italic>&lt;0.001) plaque. The percent change in fatty, fibrous, noncalcified, and total plaque was significantly different between the regressors and progressors at 30‐month follow‐up (<italic toggle="yes">P</italic>&lt;0.001 for all).</p>
                <fig position="float" fig-type="Figure" id="jah38796-fig-0001">
                  <label>Figure 1</label>
                  <caption>
                    <title>Median percent change in coronary plaque subtypes for those with regression of plaque compared with progression.</title>
                    <p>Regressors had a significant reduction in fatty, fibrous, noncalcified, and total plaque compared with progressors.</p>
                  </caption>
                  <graphic xlink:href="JAH3-12-e030071-g003" position="anchor" id="jats-graphic-1"/>
                </fig>
                <table-wrap position="float" id="jah38796-tbl-0002" content-type="Table">
                  <label>Table 2</label>
                  <caption>
                    <p>Median of Percent Change in Coronary Plaque in Regressors Compared With Progressors at 30‐Month Follow‐Up</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1">Plaque type</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Regressors ≤−2% n=100</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Progressors &gt;+2% n=121</th>
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1"><italic toggle="yes">P</italic> value<xref rid="jah38796-note-0009" ref-type="table-fn">†</xref>
</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Median of % change [IQR]</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value<xref rid="jah38796-note-0008" ref-type="table-fn">*</xref>
</th>
                        <th align="left" rowspan="1" colspan="1">Median of % change [IQR]</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value<xref rid="jah38796-note-0008" ref-type="table-fn">*</xref>
</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Fatty</td>
                        <td align="justify" rowspan="1" colspan="1">−12.5 [−20.6 to −7.1]</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="justify" rowspan="1" colspan="1">16.0 [8.0–32.6]</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Fibrous</td>
                        <td align="justify" rowspan="1" colspan="1">−8.7 [−19.5 to 1.4]</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="justify" rowspan="1" colspan="1">14.5 [1.5–26.4]</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Noncalcified</td>
                        <td align="justify" rowspan="1" colspan="1">−9.5 [−19.3 to −4.0]</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="justify" rowspan="1" colspan="1">15.1 [5.0–27.2]</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Calcified</td>
                        <td align="justify" rowspan="1" colspan="1">56.1 [−0.6 to 139.3]</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="justify" rowspan="1" colspan="1">40.8 [0.81–18.4]</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="justify" rowspan="1" colspan="1">0.76</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Total</td>
                        <td align="justify" rowspan="1" colspan="1">−3.0 [−13.7 to 6.3]</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="justify" rowspan="1" colspan="1">19.0 [7.9–33.8]</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="justify" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38796-ntgp-0003">
                    <fn id="jah38796-note-0007">
                      <p>IQR indicates interquartile range.</p>
                    </fn>
                    <fn id="jah38796-note-0008">
                      <label>*</label>
                      <p><italic toggle="yes">P</italic> value compares plaque volume at baseline with 30 months.</p>
                    </fn>
                    <fn id="jah38796-note-0009">
                      <label>
                        <sup>†</sup>
                      </label>
                      <p><italic toggle="yes">P</italic> value compares regressors with progressors.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah38796-sec-0019">
                <title>Percent Change in Characteristics at 30‐Month Follow‐Up</title>
                <p>Table <xref rid="jah38796-tbl-0003" ref-type="table">3</xref> reports median percent change in characteristics from baseline at 30‐month follow‐up for regressors compared with progressors. Regressors had a median reduction (–14.9% [IQR, −31.3 to 6.3]) in triglyceride level (from a median of 1.35–1.22 mmol/L; 120–108 mg/dL) compared with no significant change (−2.8% [IQR, −25.1 to 15.1]) in progressors (between‐group <italic toggle="yes">P</italic>=0.025). Otherwise, there were no significant differences.</p>
                <table-wrap position="float" id="jah38796-tbl-0003" content-type="Table">
                  <label>Table 3</label>
                  <caption>
                    <p>Median Percent Change from Baseline at 30‐Month Follow‐Up</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1"/>
                        <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1">Regressors ≤−2% n=100</th>
                        <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1">Progressors &gt;+2% n=121</th>
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1"><italic toggle="yes">P</italic> value</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Median [IQR]</th>
                        <th align="left" rowspan="1" colspan="1">Median [IQR]</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Clinical variable</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic BP</td>
                        <td align="left" rowspan="1" colspan="1">−4.2 [−11.7 to 5.4]</td>
                        <td align="left" rowspan="1" colspan="1">−4.8 [−11.2 to 3.3]</td>
                        <td align="left" rowspan="1" colspan="1">0.64</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diastolic BP</td>
                        <td align="left" rowspan="1" colspan="1">−4.5 [−14.1 to 1.7]</td>
                        <td align="left" rowspan="1" colspan="1">−4.7 [−11.1 to 2.2]</td>
                        <td align="left" rowspan="1" colspan="1">0.36</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Waist circumference</td>
                        <td align="left" rowspan="1" colspan="1">0.5 [−3.2 to 4.2]</td>
                        <td align="left" rowspan="1" colspan="1">0.6 [−1.6 to 3.6]</td>
                        <td align="left" rowspan="1" colspan="1">0.54</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Weight</td>
                        <td align="left" rowspan="1" colspan="1">−1.1 [−5.0 to 2.9]</td>
                        <td align="left" rowspan="1" colspan="1">−0.7 [−4.2 to 2.8]</td>
                        <td align="left" rowspan="1" colspan="1">0.82</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Body mass index</td>
                        <td align="left" rowspan="1" colspan="1">−0.2 [−4.8 to 3.9]</td>
                        <td align="left" rowspan="1" colspan="1">0.3 [−3.4 to 3.9]</td>
                        <td align="left" rowspan="1" colspan="1">0.70</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">High‐sensitivity CRP and CBC count</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">High‐sensitivity CRP</td>
                        <td align="left" rowspan="1" colspan="1">0.0 [−50.0 to 50.0]</td>
                        <td align="left" rowspan="1" colspan="1">0.0 [−56.4 to 75.8]</td>
                        <td align="left" rowspan="1" colspan="1">0.91</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">WBC count</td>
                        <td align="left" rowspan="1" colspan="1">−5.9 [−14.6 to 4.9]</td>
                        <td align="left" rowspan="1" colspan="1">−6.2 [−15.0 to 5.6]</td>
                        <td align="left" rowspan="1" colspan="1">0.78</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Monocyte count</td>
                        <td align="left" rowspan="1" colspan="1">−5.7 [−17.8 to 13.6]</td>
                        <td align="left" rowspan="1" colspan="1">−8.0 [−20.6 to 7.0]</td>
                        <td align="left" rowspan="1" colspan="1">0.38</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Neutrophil count</td>
                        <td align="left" rowspan="1" colspan="1">−4.1 [−19.8 to 11.6]</td>
                        <td align="left" rowspan="1" colspan="1">−7.3 [−20.6 to 8.8]</td>
                        <td align="left" rowspan="1" colspan="1">0.54</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lymphocyte count</td>
                        <td align="left" rowspan="1" colspan="1">−6.8 [−16.3 to 5.3]</td>
                        <td align="left" rowspan="1" colspan="1">−4.7 [−20.8 to 6.6]</td>
                        <td align="left" rowspan="1" colspan="1">0.96</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Platelet count</td>
                        <td align="left" rowspan="1" colspan="1">−7.0 [−15.4 to 1.5]</td>
                        <td align="left" rowspan="1" colspan="1">−4.7 [−16.0 to 2.2]</td>
                        <td align="left" rowspan="1" colspan="1">0.87</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Lipid profile</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total cholesterol</td>
                        <td align="left" rowspan="1" colspan="1">−5.9 [−13.7 to 9.9]</td>
                        <td align="left" rowspan="1" colspan="1">−2.0 [−10.5 to 14.1]</td>
                        <td align="left" rowspan="1" colspan="1">0.16</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Triglycerides</td>
                        <td align="left" rowspan="1" colspan="1">−14.9 [−31.3 to 6.3]</td>
                        <td align="left" rowspan="1" colspan="1">−2.8 [−25.1 to 15.1]</td>
                        <td align="left" rowspan="1" colspan="1">0.025</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">HDL‐C</td>
                        <td align="left" rowspan="1" colspan="1">0.0 [−11.3 to 10.6]</td>
                        <td align="left" rowspan="1" colspan="1">−3.6 [−10.6 to 8.5]</td>
                        <td align="left" rowspan="1" colspan="1">0.79</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL‐C</td>
                        <td align="left" rowspan="1" colspan="1">−6.1 [−19.2 to 12.0]</td>
                        <td align="left" rowspan="1" colspan="1">1.6 [−17.8 to 30.1]</td>
                        <td align="left" rowspan="1" colspan="1">0.15</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Small dense LDL‐C</td>
                        <td align="left" rowspan="1" colspan="1">−12.2 [−39.8 to 40.7]</td>
                        <td align="left" rowspan="1" colspan="1">−13.0 [−38.0 to 38.3]</td>
                        <td align="left" rowspan="1" colspan="1">0.87</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non–HDL‐C</td>
                        <td align="left" rowspan="1" colspan="1">−1.8 [−20.7 to 16.9]</td>
                        <td align="left" rowspan="1" colspan="1">−2.7 [17.3–19.2]</td>
                        <td align="left" rowspan="1" colspan="1">0.83</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Remnant cholesterol</td>
                        <td align="left" rowspan="1" colspan="1">−12.9 [−30.4 to 5.0]</td>
                        <td align="left" rowspan="1" colspan="1">−3.3 [−27.3 to 15.4]</td>
                        <td align="left" rowspan="1" colspan="1">0.084</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Biochemical profile</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Glucose</td>
                        <td align="left" rowspan="1" colspan="1">0.3 [−5.7 to 9.5]</td>
                        <td align="left" rowspan="1" colspan="1">1.6 [−6.7 to 11.3]</td>
                        <td align="left" rowspan="1" colspan="1">0.85</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hemoglobin A1c</td>
                        <td align="left" rowspan="1" colspan="1">0.0 [−3.2 to 3.6]</td>
                        <td align="left" rowspan="1" colspan="1">0.0 [−3.4 to 3.7]</td>
                        <td align="left" rowspan="1" colspan="1">0.87</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Omega‐3 fatty acid index</td>
                        <td align="left" rowspan="1" colspan="1">36.5 [−0.81 to 12.6]</td>
                        <td align="left" rowspan="1" colspan="1">18.5 [−1.2 to 94.4]</td>
                        <td align="left" rowspan="1" colspan="1">0.61</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Creatinine clearance</td>
                        <td align="left" rowspan="1" colspan="1">−7.5 [−14.5 to 1.6]</td>
                        <td align="left" rowspan="1" colspan="1">−7.6 [−14.0 to 0.4]</td>
                        <td align="left" rowspan="1" colspan="1">0.84</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Albumin‐creatinine ratio</td>
                        <td align="left" rowspan="1" colspan="1">38.0 [−31.8 to 202.2]</td>
                        <td align="left" rowspan="1" colspan="1">12.0 [−33.7 to 78.1]</td>
                        <td align="left" rowspan="1" colspan="1">0.084</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38796-ntgp-0004">
                    <fn id="jah38796-note-0010">
                      <p>BP indicates blood pressure; CBC, complete blood count; CRP, C‐reactive protein; HDL‐C, high‐density lipoprotein cholesterol; IQR, interquartile range; LDL‐C, low‐density lipoprotein cholesterol; and WBC, white blood cell.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah38796-sec-0020">
                <title>Correlations Between Changes in Lipids and Coronary Plaque</title>
                <p>The percent change in triglyceride level was significantly positively correlated with the percent change in fatty and noncalcified plaque (<italic toggle="yes">r</italic>=0.135 [<italic toggle="yes">P</italic>=0.036] and <italic toggle="yes">r</italic>=0.146 [<italic toggle="yes">P</italic>=0.024], respectively) (Table <xref rid="jah38796-tbl-0004" ref-type="table">4</xref>). The percent change in plasma omega‐3 fatty acid index was inversely correlated with triglyceride change in the total group of regressors and progressors (<italic toggle="yes">r</italic>=−0.274 [<italic toggle="yes">P</italic>&lt;0.001]) and in those with regression (<italic toggle="yes">r</italic>=−0.384 [<italic toggle="yes">P</italic>&lt;0.001]) (data not shown).</p>
                <table-wrap position="float" id="jah38796-tbl-0004" content-type="Table">
                  <label>Table 4</label>
                  <caption>
                    <p>Correlation Between Percent Change in Lipids and Coronary Plaque at 30‐Month Follow‐Up</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="3" style="border-bottom:solid 1px #000000" colspan="1">Percent change in lipids</th>
                        <th align="left" colspan="10" style="border-bottom:solid 1px #000000" rowspan="1">Percent change in coronary plaque</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Fatty</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Fibrous</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Noncalcified</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Calcified</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Total</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">
                          <italic toggle="yes">r</italic>
                        </th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                        <th align="left" rowspan="1" colspan="1">
                          <italic toggle="yes">r</italic>
                        </th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                        <th align="left" rowspan="1" colspan="1">
                          <italic toggle="yes">r</italic>
                        </th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                        <th align="left" rowspan="1" colspan="1">
                          <italic toggle="yes">r</italic>
                        </th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                        <th align="left" rowspan="1" colspan="1">
                          <italic toggle="yes">r</italic>
                        </th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Total cholesterol</td>
                        <td align="left" rowspan="1" colspan="1">0.049</td>
                        <td align="left" rowspan="1" colspan="1">0.46</td>
                        <td align="left" rowspan="1" colspan="1">−0.006</td>
                        <td align="left" rowspan="1" colspan="1">0.93</td>
                        <td align="left" rowspan="1" colspan="1">0.021</td>
                        <td align="left" rowspan="1" colspan="1">0.76</td>
                        <td align="left" rowspan="1" colspan="1">−0.050</td>
                        <td align="left" rowspan="1" colspan="1">0.45</td>
                        <td align="left" rowspan="1" colspan="1">0.016</td>
                        <td align="left" rowspan="1" colspan="1">0.81</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LDL‐C</td>
                        <td align="left" rowspan="1" colspan="1">0.045</td>
                        <td align="left" rowspan="1" colspan="1">0.51</td>
                        <td align="left" rowspan="1" colspan="1">0.038</td>
                        <td align="left" rowspan="1" colspan="1">0.57</td>
                        <td align="left" rowspan="1" colspan="1">0.048</td>
                        <td align="left" rowspan="1" colspan="1">0.47</td>
                        <td align="left" rowspan="1" colspan="1">−0.016</td>
                        <td align="left" rowspan="1" colspan="1">0.81</td>
                        <td align="left" rowspan="1" colspan="1">0.046</td>
                        <td align="left" rowspan="1" colspan="1">0.49</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HDL‐C</td>
                        <td align="left" rowspan="1" colspan="1">−0.037</td>
                        <td align="left" rowspan="1" colspan="1">0.57</td>
                        <td align="left" rowspan="1" colspan="1">−0.155</td>
                        <td align="left" rowspan="1" colspan="1">0.016</td>
                        <td align="left" rowspan="1" colspan="1">−0.134</td>
                        <td align="left" rowspan="1" colspan="1">0.039</td>
                        <td align="left" rowspan="1" colspan="1">0.042</td>
                        <td align="left" rowspan="1" colspan="1">0.52</td>
                        <td align="left" rowspan="1" colspan="1">−0.052</td>
                        <td align="left" rowspan="1" colspan="1">0.42</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Triglyceride</td>
                        <td align="left" rowspan="1" colspan="1">0.135</td>
                        <td align="left" rowspan="1" colspan="1">0.036</td>
                        <td align="left" rowspan="1" colspan="1">0.116</td>
                        <td align="left" rowspan="1" colspan="1">0.07</td>
                        <td align="left" rowspan="1" colspan="1">0.146</td>
                        <td align="left" rowspan="1" colspan="1">0.024</td>
                        <td align="left" rowspan="1" colspan="1">−0.045</td>
                        <td align="left" rowspan="1" colspan="1">0.49</td>
                        <td align="left" rowspan="1" colspan="1">0.080</td>
                        <td align="left" rowspan="1" colspan="1">0.22</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Small dense LDL‐C</td>
                        <td align="left" rowspan="1" colspan="1">0.007</td>
                        <td align="left" rowspan="1" colspan="1">0.92</td>
                        <td align="left" rowspan="1" colspan="1">0.021</td>
                        <td align="left" rowspan="1" colspan="1">0.76</td>
                        <td align="left" rowspan="1" colspan="1">0.020</td>
                        <td align="left" rowspan="1" colspan="1">0.77</td>
                        <td align="left" rowspan="1" colspan="1">−0.067</td>
                        <td align="left" rowspan="1" colspan="1">0.33</td>
                        <td align="left" rowspan="1" colspan="1">−0.014</td>
                        <td align="left" rowspan="1" colspan="1">0.84</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Non–HDL‐C</td>
                        <td align="left" rowspan="1" colspan="1">0.011</td>
                        <td align="left" rowspan="1" colspan="1">0.88</td>
                        <td align="left" rowspan="1" colspan="1">0.012</td>
                        <td align="left" rowspan="1" colspan="1">0.86</td>
                        <td align="left" rowspan="1" colspan="1">0.010</td>
                        <td align="left" rowspan="1" colspan="1">0.88</td>
                        <td align="left" rowspan="1" colspan="1">−0.033</td>
                        <td align="left" rowspan="1" colspan="1">0.63</td>
                        <td align="left" rowspan="1" colspan="1">−0.099</td>
                        <td align="left" rowspan="1" colspan="1">0.89</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">High‐sensitivity CRP</td>
                        <td align="left" rowspan="1" colspan="1">0.006</td>
                        <td align="left" rowspan="1" colspan="1">0.93</td>
                        <td align="left" rowspan="1" colspan="1">0.028</td>
                        <td align="left" rowspan="1" colspan="1">0.68</td>
                        <td align="left" rowspan="1" colspan="1">0.026</td>
                        <td align="left" rowspan="1" colspan="1">0.70</td>
                        <td align="left" rowspan="1" colspan="1">−0.001</td>
                        <td align="left" rowspan="1" colspan="1">0.99</td>
                        <td align="left" rowspan="1" colspan="1">−0.012</td>
                        <td align="left" rowspan="1" colspan="1">0.86</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Remnant cholesterol</td>
                        <td align="left" rowspan="1" colspan="1">0.105</td>
                        <td align="left" rowspan="1" colspan="1">0.11</td>
                        <td align="left" rowspan="1" colspan="1">0.108</td>
                        <td align="left" rowspan="1" colspan="1">0.10</td>
                        <td align="left" rowspan="1" colspan="1">0.123</td>
                        <td align="left" rowspan="1" colspan="1">0.06</td>
                        <td align="left" rowspan="1" colspan="1">−0.033</td>
                        <td align="left" rowspan="1" colspan="1">0.61</td>
                        <td align="left" rowspan="1" colspan="1">0.075</td>
                        <td align="left" rowspan="1" colspan="1">0.25</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38796-ntgp-0005">
                    <fn id="jah38796-note-0011">
                      <p>CRP indicates C‐reactive protein; HDL‐C, high‐density lipoprotein cholesterol; and LDL‐C, low‐density lipoprotein cholesterol.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah38796-sec-0021">
                <title>Cardiac Events in Progressors and Regressors</title>
                <p>Table <xref rid="jah38796-tbl-0005" ref-type="table">5</xref> reports the cardiac events stratified by progression or regression of coronary plaque. Compared with progressors, regressors had significantly fewer total cardiac events (22.3% vs 5.0%, <italic toggle="yes">P</italic>&lt;0.001), percutaneous coronary interventions (15.7% vs 3.0%, <italic toggle="yes">P</italic>=0.002), and unstable angina (21.5% vs 3.0%, <italic toggle="yes">P</italic>&lt;0.001). Figure <xref rid="jah38796-fig-0002" ref-type="fig">2</xref> shows the Kaplan–Meier plot for freedom from cardiovascular events. Those with progression of plaque had a 2.89‐fold increased risk of events (95% CI, 1.1–8.0; <italic toggle="yes">P</italic>=0.034).</p>
                <table-wrap position="float" id="jah38796-tbl-0005" content-type="Table">
                  <label>Table 5</label>
                  <caption>
                    <p>Cardiac Events Stratified by Progression or Regression of Coronary Fatty Plaque</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1"/>
                        <th align="left" rowspan="1" colspan="1">Progressors n=121</th>
                        <th align="left" rowspan="1" colspan="1">Regressors n=100</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Percutaneous coronary intervention, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">19 (15.7)</td>
                        <td align="left" rowspan="1" colspan="1">3 (3)</td>
                        <td align="left" rowspan="1" colspan="1">0.002</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Unstable angina, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">26 (21.5)</td>
                        <td align="left" rowspan="1" colspan="1">3 (3)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Myocardial infarction, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (1.65)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" rowspan="1" colspan="1">0.50</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Coronary artery bypass graft, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (1.65)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" rowspan="1" colspan="1">0.50</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Total incident cardiac events, n (%)<xref rid="jah38796-note-0012" ref-type="table-fn">*</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">27 (22.3)</td>
                        <td align="left" rowspan="1" colspan="1">5 (5)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38796-ntgp-0006">
                    <fn id="jah38796-note-0012">
                      <label>*</label>
                      <p>Total incident events include percutaneous coronary intervention, nonfatal myocardial infarction, and coronary artery bypass graft or unstable angina. The total incident cardiac events is less than the sum of individual events because some patients had more than 1 event.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig position="float" fig-type="Figure" id="jah38796-fig-0002">
                  <label>Figure 2</label>
                  <caption>
                    <title>Kaplan–Meier plot for freedom from cardiovascular events over 30 months in patients with coronary plaque regression compared with those with coronary plaque progression.</title>
                    <p>Those with plaque progression had a 2.9‐fold higher rate of cardiovascular events compared with those with plaque regression.</p>
                  </caption>
                  <graphic xlink:href="JAH3-12-e030071-g001" position="anchor" id="jats-graphic-3"/>
                </fig>
              </sec>
              <sec id="jah38796-sec-0022">
                <title>Baseline Predictors of Change in Fatty Plaque</title>
                <p>The univariate analysis for baseline predictors of change in fatty plaque is shown in Table <xref rid="jah38796-tbl-0006" ref-type="table">6</xref>. After multivariate adjustment including the treatment arm, non–HDL‐C level &lt;2.59 mmol/L and systolic BP &lt;125 mm Hg were significant independent predictors of coronary fatty plaque regression: the regression coefficient for systolic BP was 0.03 (95% CI, 0.012–0.048; <italic toggle="yes">P</italic>=0.001) and for non–HDL‐C was 0.014 (95% CI, 0.006–0.022; <italic toggle="yes">P</italic>=0.002).</p>
                <table-wrap position="float" id="jah38796-tbl-0006" content-type="Table">
                  <label>Table 6</label>
                  <caption>
                    <p>Univariate Analysis for Baseline Factors Predicting Change in Coronary Fatty Plaque at 30‐Month Follow‐Up</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Variable</th>
                        <th align="left" rowspan="1" colspan="1">Correlation coefficient, <italic toggle="yes">r</italic>
</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Systolic BP</td>
                        <td align="left" rowspan="1" colspan="1">0.167</td>
                        <td align="left" rowspan="1" colspan="1">0.010</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Apolipoprotein B</td>
                        <td align="left" rowspan="1" colspan="1">0.169</td>
                        <td align="left" rowspan="1" colspan="1">0.011</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Non–HDL‐C</td>
                        <td align="left" rowspan="1" colspan="1">0.158</td>
                        <td align="left" rowspan="1" colspan="1">0.017</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diastolic BP</td>
                        <td align="left" rowspan="1" colspan="1">0.108</td>
                        <td align="left" rowspan="1" colspan="1">0.094</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Percent small dense LDL‐C</td>
                        <td align="left" rowspan="1" colspan="1">0.109</td>
                        <td align="left" rowspan="1" colspan="1">0.10</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Neutrophil count</td>
                        <td align="left" rowspan="1" colspan="1">0.056</td>
                        <td align="left" rowspan="1" colspan="1">0.39</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">DHA</td>
                        <td align="left" rowspan="1" colspan="1">0.053</td>
                        <td align="left" rowspan="1" colspan="1">0.44</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Triglyceride level</td>
                        <td align="left" rowspan="1" colspan="1">0.052</td>
                        <td align="left" rowspan="1" colspan="1">0.44</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">WBC count</td>
                        <td align="left" rowspan="1" colspan="1">0.050</td>
                        <td align="left" rowspan="1" colspan="1">0.44</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Waist circumference</td>
                        <td align="left" rowspan="1" colspan="1">0.049</td>
                        <td align="left" rowspan="1" colspan="1">0.45</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Body mass index</td>
                        <td align="left" rowspan="1" colspan="1">0.042</td>
                        <td align="left" rowspan="1" colspan="1">0.51</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LDL‐C</td>
                        <td align="left" rowspan="1" colspan="1">0.040</td>
                        <td align="left" rowspan="1" colspan="1">0.54</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hemoglobin A1c</td>
                        <td align="left" rowspan="1" colspan="1">0.039</td>
                        <td align="left" rowspan="1" colspan="1">0.54</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">EPA</td>
                        <td align="left" rowspan="1" colspan="1">0.040</td>
                        <td align="left" rowspan="1" colspan="1">0.56</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Albumin‐creatinine ratio</td>
                        <td align="left" rowspan="1" colspan="1">0.018</td>
                        <td align="left" rowspan="1" colspan="1">0.78</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Omega‐3 fatty acid index</td>
                        <td align="left" rowspan="1" colspan="1">0.014</td>
                        <td align="left" rowspan="1" colspan="1">0.83</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Monocyte count</td>
                        <td align="left" rowspan="1" colspan="1">0.011</td>
                        <td align="left" rowspan="1" colspan="1">0.87</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lymphocyte count</td>
                        <td align="left" rowspan="1" colspan="1">−0.008</td>
                        <td align="left" rowspan="1" colspan="1">0.90</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Platelet count</td>
                        <td align="left" rowspan="1" colspan="1">0.005</td>
                        <td align="left" rowspan="1" colspan="1">0.94</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age</td>
                        <td align="left" rowspan="1" colspan="1">0.003</td>
                        <td align="left" rowspan="1" colspan="1">0.96</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38796-ntgp-0007">
                    <fn id="jah38796-note-0013">
                      <p>BP indicates blood pressure; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; and WBC, white blood cell.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah38796-sec-0023">
                <title>Results Stratified by BP Status</title>
                <p>A significant interaction term between randomization treatment arm and hypertension status was noted in the prediction of noncalcified (<italic toggle="yes">P</italic>=0.044) and total (<italic toggle="yes">P</italic>=0.008) plaque. Therefore, we stratified the analysis based on BP status. Table <xref rid="jah38796-tbl-0007" ref-type="table">7</xref> reports baseline characteristics stratified by BP status. Compared with normotensive patients, hypertensive patients were significantly younger and had significantly higher baseline coronary artery calcium score, higher systolic BP, lower creatinine clearance, higher level of monocytes, and higher use of angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, and hydrochlorothiazide. Median baseline coronary artery calcium for normotensive patients was 213.3 (IQR, 42.2–630.2) and for hypertensive patients was 475.5 (IQR, 154.9–1156.3) (between‐group <italic toggle="yes">P</italic>=0.003).</p>
                <table-wrap position="float" id="jah38796-tbl-0007" content-type="Table">
                  <label>Table 7</label>
                  <caption>
                    <p>Baseline Characteristics Stratified by BP Status</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1"/>
                        <th align="left" rowspan="1" colspan="1">Hypertensive (n=200)</th>
                        <th align="left" rowspan="1" colspan="1">Normotensive (n=40)</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Demographic characteristics</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, mean±SD, y</td>
                        <td align="left" rowspan="1" colspan="1">58.3±8.0</td>
                        <td align="left" rowspan="1" colspan="1">63.9±7.3</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male sex, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">165 (84.6)</td>
                        <td align="left" rowspan="1" colspan="1">33 (80.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.51</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Inclusion criteria (may have &gt;1), n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of MI</td>
                        <td align="left" rowspan="1" colspan="1">84 (43.1)</td>
                        <td align="left" rowspan="1" colspan="1">21 (51.2)</td>
                        <td align="left" rowspan="1" colspan="1">0.45</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of PCI</td>
                        <td align="left" rowspan="1" colspan="1">116 (59.5)</td>
                        <td align="left" rowspan="1" colspan="1">27 (65.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.52</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of CABG</td>
                        <td align="left" rowspan="1" colspan="1">50 (25.6)</td>
                        <td align="left" rowspan="1" colspan="1">6 (14.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.26</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Cardiovascular risk factors, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">History of diabetes</td>
                        <td align="left" rowspan="1" colspan="1">54 (27.7)</td>
                        <td align="left" rowspan="1" colspan="1">9 (22.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.45</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Coronary calcium score, median [IQR]</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Baseline CAC score, Agatston units</td>
                        <td align="left" rowspan="1" colspan="1">475.5 [154.9–1156.3]</td>
                        <td align="left" rowspan="1" colspan="1">213.3 [42.2–630.2]</td>
                        <td align="left" rowspan="1" colspan="1">0.003</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Plaque volume, mm<sup>3</sup>/mm, median [IQR]</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fatty</td>
                        <td align="left" rowspan="1" colspan="1">8.7 [5.3–13.7]</td>
                        <td align="left" rowspan="1" colspan="1">10.6 [6.1–15.1]</td>
                        <td align="left" rowspan="1" colspan="1">0.25</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fibrous</td>
                        <td align="left" rowspan="1" colspan="1">15.9 [9.2–23.4]</td>
                        <td align="left" rowspan="1" colspan="1">20.0 [10.6–25.4]</td>
                        <td align="left" rowspan="1" colspan="1">0.14</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Noncalcified</td>
                        <td align="left" rowspan="1" colspan="1">24.9 [14.3–36.6]</td>
                        <td align="left" rowspan="1" colspan="1">30.8 [16.4–40.8]</td>
                        <td align="left" rowspan="1" colspan="1">0.16</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total plaque</td>
                        <td align="left" rowspan="1" colspan="1">33.1 [18.1–47.2]</td>
                        <td align="left" rowspan="1" colspan="1">37.3 [22.3–51.0]</td>
                        <td align="left" rowspan="1" colspan="1">0.22</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Anthropometrics and BP, mean±SD</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Weight, kg</td>
                        <td align="left" rowspan="1" colspan="1">91.5±13.7</td>
                        <td align="left" rowspan="1" colspan="1">89.1±13.6</td>
                        <td align="left" rowspan="1" colspan="1">0.15</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">30.7±3. 5</td>
                        <td align="left" rowspan="1" colspan="1">30.0±3.5</td>
                        <td align="left" rowspan="1" colspan="1">0.13</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Waist circumference, cm</td>
                        <td align="left" rowspan="1" colspan="1">106.8±10.4</td>
                        <td align="left" rowspan="1" colspan="1">104.1±9.0</td>
                        <td align="left" rowspan="1" colspan="1">0.061</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic BP, mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">125.8±13.6</td>
                        <td align="left" rowspan="1" colspan="1">117.4±15.8</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diastolic BP, mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">73.7±9.8</td>
                        <td align="left" rowspan="1" colspan="1">71.8±9.3</td>
                        <td align="left" rowspan="1" colspan="1">0.13</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Biochemical profile, mean±SD, except high‐sensitivity CRP and omega‐3 fatty acid index, which are median [IQR]</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Glucose, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">5.76±1.54</td>
                        <td align="left" rowspan="1" colspan="1">5.69±1.47</td>
                        <td align="left" rowspan="1" colspan="1">0.79</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">103.8±27.8</td>
                        <td align="left" rowspan="1" colspan="1">102.6±26.4</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hemoglobin A1c, %</td>
                        <td align="left" rowspan="1" colspan="1">5.8±0.80</td>
                        <td align="left" rowspan="1" colspan="1">6.1±1.1</td>
                        <td align="left" rowspan="1" colspan="1">0.81</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Creatinine clearance, mL/min</td>
                        <td align="left" rowspan="1" colspan="1">99.7±26.6</td>
                        <td align="left" rowspan="1" colspan="1">109.9±26.4</td>
                        <td align="left" rowspan="1" colspan="1">0.025</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">High‐sensitivity CRP, mg/L</td>
                        <td align="left" rowspan="1" colspan="1">0.80 [0.40–2.7]</td>
                        <td align="left" rowspan="1" colspan="1">0.70 [0.40–1.1]</td>
                        <td align="left" rowspan="1" colspan="1">0.20</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Omega‐3 fatty acid Index</td>
                        <td align="left" rowspan="1" colspan="1">3.29 [2.60–4.16]</td>
                        <td align="left" rowspan="1" colspan="1">2.99 [2.33–4.22]</td>
                        <td align="left" rowspan="1" colspan="1">0.39</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Lipid levels, mean±SD, except triglyceride, which is median [IQR]</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">HDL‐C, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">1.23±0.40</td>
                        <td align="left" rowspan="1" colspan="1">1.22±0.24</td>
                        <td align="left" rowspan="1" colspan="1">0.79</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">47.4±15.3</td>
                        <td align="left" rowspan="1" colspan="1">47.0±9.4</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL‐C, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">2.01±0.68</td>
                        <td align="left" rowspan="1" colspan="1">2.04±0.81</td>
                        <td align="left" rowspan="1" colspan="1">0.84</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">77.8±26.3</td>
                        <td align="left" rowspan="1" colspan="1">78.8±31.4</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total cholesterol, mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">3.94±0.92</td>
                        <td align="left" rowspan="1" colspan="1">3.88±1.00</td>
                        <td align="left" rowspan="1" colspan="1">0.70</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">152.4±35.5</td>
                        <td align="left" rowspan="1" colspan="1">150.0±38.7</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Triglyceride, median [IQR], mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">1.33 [0.94–1.89]</td>
                        <td align="left" rowspan="1" colspan="1">1.29 [0.80–1.72]</td>
                        <td align="left" rowspan="1" colspan="1">0.33</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">mg/dL</td>
                        <td align="left" rowspan="1" colspan="1">118.0 [83.0–167.0]</td>
                        <td align="left" rowspan="1" colspan="1">114.0 [71.3–152.3]</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">CBC, mean±SD</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">WBCs, 10<sup>9</sup> cells/L</td>
                        <td align="left" rowspan="1" colspan="1">6.7±2.3</td>
                        <td align="left" rowspan="1" colspan="1">6.3±1.3</td>
                        <td align="left" rowspan="1" colspan="1">0.29</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Monocytes, cells/μL</td>
                        <td align="left" rowspan="1" colspan="1">540±167</td>
                        <td align="left" rowspan="1" colspan="1">482±160</td>
                        <td align="left" rowspan="1" colspan="1">0.044</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Neutrophils, cells/μL</td>
                        <td align="left" rowspan="1" colspan="1">4206±1512</td>
                        <td align="left" rowspan="1" colspan="1">3960±1184</td>
                        <td align="left" rowspan="1" colspan="1">0.33</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lymphocytes, cells/μL</td>
                        <td align="left" rowspan="1" colspan="1">1757±1537</td>
                        <td align="left" rowspan="1" colspan="1">1699±424</td>
                        <td align="left" rowspan="1" colspan="1">0.81</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Platelets, cells/μL</td>
                        <td align="left" rowspan="1" colspan="1">191±51</td>
                        <td align="left" rowspan="1" colspan="1">196±47</td>
                        <td align="left" rowspan="1" colspan="1">0.54</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Medications, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Statin</td>
                        <td align="left" rowspan="1" colspan="1">185 (94.9)</td>
                        <td align="left" rowspan="1" colspan="1">38 (92.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.58</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin</td>
                        <td align="left" rowspan="1" colspan="1">184 (94.4)</td>
                        <td align="left" rowspan="1" colspan="1">41 (100)</td>
                        <td align="left" rowspan="1" colspan="1">0.12</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ACEI</td>
                        <td align="left" rowspan="1" colspan="1">116 (59.5)</td>
                        <td align="left" rowspan="1" colspan="1">15 (36.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.007</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ARB</td>
                        <td align="left" rowspan="1" colspan="1">40 (20.5)</td>
                        <td align="left" rowspan="1" colspan="1">3 (7.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.047</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hydrochlorothiazide</td>
                        <td align="left" rowspan="1" colspan="1">43 (22.1)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Furosemide</td>
                        <td align="left" rowspan="1" colspan="1">17 (8.7)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2.4)</td>
                        <td align="left" rowspan="1" colspan="1">0.17</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Calcium channel blocker</td>
                        <td align="left" rowspan="1" colspan="1">56 (28.7)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" rowspan="1" colspan="1">0.051</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">β‐Blocker</td>
                        <td align="left" rowspan="1" colspan="1">144 (73.8)</td>
                        <td align="left" rowspan="1" colspan="1">22 (53.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.12</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38796-ntgp-0008">
                    <fn id="jah38796-note-0014">
                      <p>ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft; CBC, complete blood count; CAC, coronary artery calcium; CRP, C‐reactive protein; HDL‐C, high‐density lipoprotein cholesterol; IQR, interquartile range; LDL‐C, low‐density lipoprotein cholesterol; MI, myocardial infarction; PCI, percutaneous coronary intervention; and WBC, white blood cell.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Table <xref rid="jah38796-tbl-0008" ref-type="table">8</xref> reports changes at 30‐month follow‐up for characteristics stratified by BP status. Both normotensive and hypertensive patients taking EPA+DHA had a significant reduction in triglyceride level compared with their respective control groups (20.7% vs 11.5%, respectively) (graphed in Figure <xref rid="jah38796-fig-0003" ref-type="fig">3</xref>). Normotensive patients taking EPA+DHA had a 2.2% reduction in WBC count compared with a significant 16% increase in control for a mean difference of 18.2% (<italic toggle="yes">P</italic>=0.013) (Table <xref rid="jah38796-tbl-0008" ref-type="table">8</xref>). Figure <xref rid="jah38796-fig-0003" ref-type="fig">3</xref> reports that normotensive patients taking EPA+DHA also had a reduction in neutrophil count (mean −6.2% [95% CI, −15.9 to 3.5]) compared with a significant 30.4% increase (95% CI, 0.84–59.9) in control for a 36.6% difference (<italic toggle="yes">P</italic>=0.022), suggesting lower levels of inflammation in the normotensive patients taking EPA and DHA. Hypertensive patients had no difference in WBC or neutrophil count by treatment assignment (Figure <xref rid="jah38796-fig-0003" ref-type="fig">3</xref>). When examined by neutrophil/lymphocyte ratio (NLR), Table <xref rid="jah38796-tbl-0009" ref-type="table">9</xref> reports that normotensive patients taking EPA+DHA had a significant reduction in NLR (2.64±0.87 at baseline vs 2.39±1.03 at 30‐month follow‐up, <italic toggle="yes">P</italic>=0.024), whereas normotensive patients taking control had an increase that approached significance: 2.09±0.85 at baseline versus 2.47±0.96 at 30‐month follow‐up (<italic toggle="yes">P</italic>=0.064). In contrast, hypertensive patients taking EPA+DHA had no significant difference. No other changes between normotensive and hypertensive patients taking EPA+DHA were noted.</p>
                <table-wrap position="float" id="jah38796-tbl-0008" content-type="Table">
                  <label>Table 8</label>
                  <caption>
                    <p>Percent Change in Characteristics at 30‐Month Follow‐Up in the Control and EPA+DHA Groups Stratified by BP Status</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="3" style="border-bottom:solid 1px #000000" colspan="1"/>
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" rowspan="1">Hypertensive</th>
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" rowspan="1">Normotensive</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" rowspan="1">Percent change from baseline</th>
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" rowspan="1">Percent change from baseline</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Controls (n=101)</th>
                        <th align="left" rowspan="1" colspan="1">EPA+DHA (n=99)</th>
                        <th align="left" rowspan="1" colspan="1">Mean difference in % change</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value<xref rid="jah38796-note-0016" ref-type="table-fn">*</xref>
</th>
                        <th align="left" rowspan="1" colspan="1">Controls (n=13)</th>
                        <th align="left" rowspan="1" colspan="1">EPA+DHA (n=27)</th>
                        <th align="left" rowspan="1" colspan="1">Mean difference in % change</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value<xref rid="jah38796-note-0016" ref-type="table-fn">*</xref>
</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="9" rowspan="1">Anthropometrics and BP, mean (95% CI)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Weight</td>
                        <td align="left" rowspan="1" colspan="1">−1.5 (−2.7 to −0.37)</td>
                        <td align="left" rowspan="1" colspan="1">−0.82 (−2.2 to 0.61)</td>
                        <td align="left" rowspan="1" colspan="1">0.72 (−1.1 to 2.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.44</td>
                        <td align="left" rowspan="1" colspan="1">0.66 (−1.7 to 3.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.51 (−2.3 to 3.4)</td>
                        <td align="left" rowspan="1" colspan="1">−0.14 (−4.5 to 4.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.95</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI<xref rid="jah38796-note-0017" ref-type="table-fn">†</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">−0.88 (−2.1 to 0.29)</td>
                        <td align="left" rowspan="1" colspan="1">−0.34 (−1.7 to 1.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.42 (−1.4 to 2.2)</td>
                        <td align="left" rowspan="1" colspan="1">0.64</td>
                        <td align="left" rowspan="1" colspan="1">1.2 (−1.4 to 3.8)</td>
                        <td align="left" rowspan="1" colspan="1">10.2 (−8.8 to 29.2)</td>
                        <td align="left" rowspan="1" colspan="1">9.0 (−18.7 to 36.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.51</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Waist, cm</td>
                        <td align="left" rowspan="1" colspan="1">1.3 (0.26 to 2.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.90 (−0.24 to 2.0)</td>
                        <td align="left" rowspan="1" colspan="1">−0.47 (−2.0 to 1.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.54</td>
                        <td align="left" rowspan="1" colspan="1">2.2 (0.43 to 4.0)</td>
                        <td align="left" rowspan="1" colspan="1">3.1 (0.86 to 5.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.85 (−2.6 to 4.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.62</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic BP</td>
                        <td align="left" rowspan="1" colspan="1">−0.52 (−3.2 to 2.2)</td>
                        <td align="left" rowspan="1" colspan="1">0.010 (−2.1 to 2.2)</td>
                        <td align="left" rowspan="1" colspan="1">0.57 (−2.9 to 4.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.75</td>
                        <td align="left" rowspan="1" colspan="1">2.6 (−5.9 to 11.1)</td>
                        <td align="left" rowspan="1" colspan="1">−0.21 (−4.5 to 4.1)</td>
                        <td align="left" rowspan="1" colspan="1">−2.8 (−11.1 to 5.4)</td>
                        <td align="left" rowspan="1" colspan="1">0.49</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diastolic BP</td>
                        <td align="left" rowspan="1" colspan="1">−4.1 (−6.4 to −1.7)</td>
                        <td align="left" rowspan="1" colspan="1">−3.0 (−5.7 to −0.34)</td>
                        <td align="left" rowspan="1" colspan="1">1.0 (−2.5 to 4.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.57</td>
                        <td align="left" rowspan="1" colspan="1">1.4 (−3.2 to 6.1)</td>
                        <td align="left" rowspan="1" colspan="1">1.2 (−3.6 to 6.0)</td>
                        <td align="left" rowspan="1" colspan="1">−0.23 (−6.7 to 6.2)</td>
                        <td align="left" rowspan="1" colspan="1">0.95</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="9" rowspan="1">Biochemical profile, mean (95% CI), except high‐sensitivity CRP and omega‐3 fatty acid index, which are median [IQR]</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Glucose</td>
                        <td align="left" rowspan="1" colspan="1">5.4 (0.91–10.0)</td>
                        <td align="left" rowspan="1" colspan="1">9.0 (2.9–15.0)</td>
                        <td align="left" rowspan="1" colspan="1">3.5 (−3.9 to 11.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.35</td>
                        <td align="left" rowspan="1" colspan="1">−2.1 (−11.8 to 7.6)</td>
                        <td align="left" rowspan="1" colspan="1">4.7 (−1.4 to 10.8)</td>
                        <td align="left" rowspan="1" colspan="1">6.8 (−3.9 to 17.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.21</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hemoglobin A1c</td>
                        <td align="left" rowspan="1" colspan="1">1.97 (−0.24 to 3.8)</td>
                        <td align="left" rowspan="1" colspan="1">0.55 (−0.8 to 1.9)</td>
                        <td align="left" rowspan="1" colspan="1">−0.21 (−2.9 to 2.4)</td>
                        <td align="left" rowspan="1" colspan="1">0.88</td>
                        <td align="left" rowspan="1" colspan="1">−0.81 (−3.1 to 1.5)</td>
                        <td align="left" rowspan="1" colspan="1">2.9 (−0.72 to 6.6)</td>
                        <td align="left" rowspan="1" colspan="1">3.8 (−1.8 to 9.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.18</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Creatinine clearance</td>
                        <td align="left" rowspan="1" colspan="1">−7.56 (−10.7 to −4.4)</td>
                        <td align="left" rowspan="1" colspan="1">−5.3 (−8.4 to −2.3)</td>
                        <td align="left" rowspan="1" colspan="1">2.2 (−2.1 to 6.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.31</td>
                        <td align="left" rowspan="1" colspan="1">−5.9 (−15.8 to 4.0)</td>
                        <td align="left" rowspan="1" colspan="1">−2.0 (−9.2 to 5.2)</td>
                        <td align="left" rowspan="1" colspan="1">3.9 (−8.9 to 16.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.54</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">High‐sensitivity CRP</td>
                        <td align="left" rowspan="1" colspan="1">0 [−50.0 to 88.0]</td>
                        <td align="left" rowspan="1" colspan="1">−13.3 [−50.0 to 33.2]</td>
                        <td align="left" rowspan="1" colspan="1">0.80</td>
                        <td align="left" rowspan="1" colspan="1">0.13</td>
                        <td align="left" rowspan="1" colspan="1">33.3 [−20.5 to 482.7]</td>
                        <td align="left" rowspan="1" colspan="1">0 [−40.5 to 141.1]</td>
                        <td align="left" rowspan="1" colspan="1">0.55</td>
                        <td align="left" rowspan="1" colspan="1">0.34</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Omega‐3 fatty acid Index</td>
                        <td align="left" rowspan="1" colspan="1">1.39 [−9.27 to 13.69]</td>
                        <td align="left" rowspan="1" colspan="1">95.33 [51.89–159.16]</td>
                        <td align="left" rowspan="1" colspan="1">96.72<xref rid="jah38796-note-0018" ref-type="table-fn">‡</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="left" rowspan="1" colspan="1">9.54 [3.94–21.17]</td>
                        <td align="left" rowspan="1" colspan="1">134.50 [42.98–175.46]</td>
                        <td align="left" rowspan="1" colspan="1">124.96<xref rid="jah38796-note-0018" ref-type="table-fn">‡</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="9" rowspan="1">Lipid levels, mean (95% CI), except triglyceride, which is median [IQR]</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">HDL‐C</td>
                        <td align="left" rowspan="1" colspan="1">−3.4 (−6.7 to −0.01)</td>
                        <td align="left" rowspan="1" colspan="1">2.2 (−2.1 to 6.5)</td>
                        <td align="left" rowspan="1" colspan="1">5.6 (0.18–10.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.043</td>
                        <td align="left" rowspan="1" colspan="1">1.8 (−7.2 to 10.8)</td>
                        <td align="left" rowspan="1" colspan="1">−1.1 (−7.2 to 4.9)</td>
                        <td align="left" rowspan="1" colspan="1">−2.9 (−13.3 to 7.4)</td>
                        <td align="left" rowspan="1" colspan="1">0.57</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">LDL‐C</td>
                        <td align="left" rowspan="1" colspan="1">5.0 (−2.1 to 12.2)</td>
                        <td align="left" rowspan="1" colspan="1">6.9 (−2.2 to 16.1)</td>
                        <td align="left" rowspan="1" colspan="1">1.9 (−9.6 to 13.4)</td>
                        <td align="left" rowspan="1" colspan="1">0.75</td>
                        <td align="left" rowspan="1" colspan="1">4.8 (−8.4 to 18.1)</td>
                        <td align="left" rowspan="1" colspan="1">13.1 (−3.5 to 29.7)</td>
                        <td align="left" rowspan="1" colspan="1">8.3 (−16.9 to 33.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.51</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total cholesterol</td>
                        <td align="left" rowspan="1" colspan="1">1.6 (−2.5 to 5.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.32 (−4.9 to 5.6)</td>
                        <td align="left" rowspan="1" colspan="1">−1.25 (−7.8 to 5.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.71</td>
                        <td align="left" rowspan="1" colspan="1">1.5 (−6.7 to 9.7)</td>
                        <td align="left" rowspan="1" colspan="1">2.3 (−7.2 to 11.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.84 (−13.8 to 15.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.91</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Triglycerides</td>
                        <td align="left" rowspan="1" colspan="1">0.0 [−17.5 to 50.9]</td>
                        <td align="left" rowspan="1" colspan="1">−11.5 [−33.7 to 13.1]</td>
                        <td align="left" rowspan="1" colspan="1">−4.2<xref rid="jah38796-note-0018" ref-type="table-fn">‡</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.011</td>
                        <td align="left" rowspan="1" colspan="1">−7.2 [−29.8 to 16.6]</td>
                        <td align="left" rowspan="1" colspan="1">−20.7 [−32.5 to −1.5]</td>
                        <td align="left" rowspan="1" colspan="1">−14.1<xref rid="jah38796-note-0018" ref-type="table-fn">‡</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.32</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="9" rowspan="1">CBC, mean (95% CI)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">WBC count</td>
                        <td align="left" rowspan="1" colspan="1">−4.5 (−8.7 to −0.35)</td>
                        <td align="left" rowspan="1" colspan="1">−5.4 (−10.0 to −0.75)</td>
                        <td align="left" rowspan="1" colspan="1">−0.89 (−7.1 to 5.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.78</td>
                        <td align="left" rowspan="1" colspan="1">16.0 (2.0 to 30.1)</td>
                        <td align="left" rowspan="1" colspan="1">−2.2 (−9.8 to 5.4)</td>
                        <td align="left" rowspan="1" colspan="1">−18.2 (−32.6 to −4.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.013</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Monocytes</td>
                        <td align="left" rowspan="1" colspan="1">−7.1 (−11.6 to −2.7)</td>
                        <td align="left" rowspan="1" colspan="1">−4.7 (−9.1 to −0.30)</td>
                        <td align="left" rowspan="1" colspan="1">2.4 (−3.8 to 8.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.44</td>
                        <td align="left" rowspan="1" colspan="1">12.9 (−5.8 to 31.6)</td>
                        <td align="left" rowspan="1" colspan="1">3.4 (−11.8 to 18.7)</td>
                        <td align="left" rowspan="1" colspan="1">−9.5 (−34.6 to 15.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.45</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Neutrophils</td>
                        <td align="left" rowspan="1" colspan="1">−1.1 (−7.4 to 5.2)</td>
                        <td align="left" rowspan="1" colspan="1">−2.7 (−9.5 to 4.0)</td>
                        <td align="left" rowspan="1" colspan="1">−1.6 (−10.8 to 7.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.73</td>
                        <td align="left" rowspan="1" colspan="1">30.4 (0.84 to 59.9)</td>
                        <td align="left" rowspan="1" colspan="1">−6.2 (−15.9 to 3.5)</td>
                        <td align="left" rowspan="1" colspan="1">−36.6 (−67.2 to −6.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.022</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lymphocytes</td>
                        <td align="left" rowspan="1" colspan="1">−6.1 (−10.3 to −2.0)</td>
                        <td align="left" rowspan="1" colspan="1">−5.4 (−9.7 to −1.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.80 (−5.2 to 6.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.80</td>
                        <td align="left" rowspan="1" colspan="1">3.6 (−8.8 to 15.9)</td>
                        <td align="left" rowspan="1" colspan="1">5.8 (−3.2 to 14.8)</td>
                        <td align="left" rowspan="1" colspan="1">2.3 (−12.9 to 17.4)</td>
                        <td align="left" rowspan="1" colspan="1">0.77</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Platelets</td>
                        <td align="left" rowspan="1" colspan="1">−6.9 (−10.2 to −3.6)</td>
                        <td align="left" rowspan="1" colspan="1">32.0 (−14.2 to 78.2)</td>
                        <td align="left" rowspan="1" colspan="1">38.9 (−7.5 to 83.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.087</td>
                        <td align="left" rowspan="1" colspan="1">−0.28 (−9.2 to 8.7)</td>
                        <td align="left" rowspan="1" colspan="1">−3.1 (−7.7 to 1.5)</td>
                        <td align="left" rowspan="1" colspan="1">−2.8 (−11.5 to 5.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.52</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38796-ntgp-0009">
                    <fn id="jah38796-note-0015">
                      <p>BMI indicates body mass index; BP, blood pressure; CBC, complete blood count; CRP, C‐reactive protein; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HDL‐C, high‐density lipoprotein cholesterol; IQR, interquartile range; LDL‐C, low‐density lipoprotein cholesterol; and WBC, white blood cell.</p>
                    </fn>
                    <fn id="jah38796-note-0016">
                      <label>*</label>
                      <p><italic toggle="yes">P</italic> values calculated using <italic toggle="yes">t</italic> test except for triglycerides and high‐sensitivity CRP, where a Mann–Whitney <italic toggle="yes">U</italic> test was used.</p>
                    </fn>
                    <fn id="jah38796-note-0017">
                      <label>
                        <sup>†</sup>
                      </label>
                      <p>Calculated as weight in kilograms divided by height in meters squared.</p>
                    </fn>
                    <fn id="jah38796-note-0018">
                      <label>
                        <sup>‡</sup>
                      </label>
                      <p>Median of difference in percent change; therefore, no 95% CI can be calculated.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig position="float" fig-type="Figure" id="jah38796-fig-0003">
                  <label>Figure 3</label>
                  <caption>
                    <title>Effect of EPA plus DHA on triglyceride level and neutrophil count in normotensive and hypertensive patients.</title>
                    <p>Normotensive patients taking EPA+DHA had a reduction in neutrophil count (mean −6.2% [95% CI, −15.9 to 3.5]) compared with a significant 30.4% increase (95% CI, 0.84–59.9) in control for a 36.6% difference (<italic toggle="yes">P</italic>=0.022), suggesting lower levels of inflammation in the normotensive patients taking EPA and DHA. Hypertensive patients had no difference in neutrophil count by treatment assignment. Both triglycerides and neutrophil count are markers of inflammation. Diff indicates difference; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; and NS, nonsignificant.</p>
                  </caption>
                  <graphic xlink:href="JAH3-12-e030071-g002" position="anchor" id="jats-graphic-5"/>
                </fig>
                <table-wrap position="float" id="jah38796-tbl-0009" content-type="Table">
                  <label>Table 9</label>
                  <caption>
                    <p>Effect of EPA+DHA on Neutrophil Lymphocyte Ratio in Normotensive and Hypertensive Patients</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" rowspan="1">Neutrophil lymphocyte ratio</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1"/>
                        <th align="left" rowspan="1" colspan="1">Baseline, mean±SD</th>
                        <th align="left" rowspan="1" colspan="1">30 months, mean±SD</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Normotensive patients</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">EPA+DHA</td>
                        <td align="left" rowspan="1" colspan="1">2.64±0.87</td>
                        <td align="left" rowspan="1" colspan="1">2.39±1.03</td>
                        <td align="left" rowspan="1" colspan="1">0.024</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Control</td>
                        <td align="left" rowspan="1" colspan="1">2.09±0.85</td>
                        <td align="left" rowspan="1" colspan="1">2.47±0.96</td>
                        <td align="left" rowspan="1" colspan="1">0.064</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Hypertensive patients</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">EPA+DHA</td>
                        <td align="left" rowspan="1" colspan="1">2.76±1.36</td>
                        <td align="left" rowspan="1" colspan="1">2.72±1.50</td>
                        <td align="left" rowspan="1" colspan="1">0.25</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Control</td>
                        <td align="left" rowspan="1" colspan="1">2.93±1.50</td>
                        <td align="left" rowspan="1" colspan="1">2.95±1.61</td>
                        <td align="left" rowspan="1" colspan="1">0.58</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38796-ntgp-0010">
                    <fn id="jah38796-note-0019">
                      <p>DHA indicates docosahexaenoic acid; and EPA, eicosapentaenoic acid.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Figure <xref rid="jah38796-fig-0004" ref-type="fig">4</xref> (data in Table <xref rid="jah38796-tbl-0010" ref-type="table">10</xref>) shows changes in coronary plaque volume at 30‐month follow‐up stratified by BP status. Compared with control, normotensive patients taking EPA+DHA had regression of fibrous (<italic toggle="yes">P</italic>=0.008), noncalcified (<italic toggle="yes">P</italic>=0.008), and total (<italic toggle="yes">P</italic>=0.003) plaque. In contrast, there was no difference in percent change in any of the plaque subtypes in hypertensive patients taking EPA+DHA compared with control. These findings suggest that the effect of EPA+DHA supplementation is modified by BP status, and normotensive patients may have greater benefit. The change in noncalcified plaque volume correlated positively with the change in triglyceride level in normotensive patients (<italic toggle="yes">r</italic>=0.35 [<italic toggle="yes">P</italic>=0.034]).</p>
                <fig position="float" fig-type="Figure" id="jah38796-fig-0004">
                  <label>Figure 4</label>
                  <caption>
                    <title>EPA and DHA are associated with regression of noncalcified and total plaque in normotensive but not hypertensive patients.</title>
                    <p>The change in noncalcified plaque correlated positively with the change in triglyceride level in normotensive patients (<italic toggle="yes">r</italic>=0.35 [<italic toggle="yes">P</italic>=0.034]). DHA indicates docosahexaenoic acid; and EPA, eicosapentaenoic acid.</p>
                  </caption>
                  <graphic xlink:href="JAH3-12-e030071-g004" position="anchor" id="jats-graphic-7"/>
                </fig>
                <table-wrap position="float" id="jah38796-tbl-0010" content-type="Table">
                  <label>Table 10</label>
                  <caption>
                    <p>Percent Change in Coronary Plaque in EPA+DHA and Control Groups Stratified by BP Status</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1"/>
                        <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1">Controls (n=13)</th>
                        <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1">EPA+DHA (n=27)</th>
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1"><italic toggle="yes">P</italic> value</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Percent change, median [IQR]</th>
                        <th align="left" rowspan="1" colspan="1">Percent change, median [IQR]</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Normotensive</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fatty</td>
                        <td align="left" rowspan="1" colspan="1">11.9 [−11.9 to 47.0]</td>
                        <td align="left" rowspan="1" colspan="1">0.22 [−17.3 to 13.1]</td>
                        <td align="left" rowspan="1" colspan="1">0.11</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fibrous</td>
                        <td align="left" rowspan="1" colspan="1">13.2 [−3.5 to 34.0]</td>
                        <td align="left" rowspan="1" colspan="1">−7.6 [−20.7 to 2.6]<xref rid="jah38796-note-0021" ref-type="table-fn">*</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.008</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Noncalcified</td>
                        <td align="left" rowspan="1" colspan="1">11.3 [3.8–28.6]</td>
                        <td align="left" rowspan="1" colspan="1">−7.2 [−19.9 to 5.8]<xref rid="jah38796-note-0022" ref-type="table-fn">†</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.008</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Calcified</td>
                        <td align="left" rowspan="1" colspan="1">96.3 [−5.2 to 131.2]</td>
                        <td align="left" rowspan="1" colspan="1">7.7 [−28.8 to 79.0]</td>
                        <td align="left" rowspan="1" colspan="1">0.096</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td>
                        <td align="left" rowspan="1" colspan="1">15.5 [4.0–50.0]</td>
                        <td align="left" rowspan="1" colspan="1">−2.6 [−15.4 to 12.5]</td>
                        <td align="left" rowspan="1" colspan="1">0.003</td>
                      </tr>
                    </tbody>
                  </table>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1"/>
                        <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1">Controls n=101</th>
                        <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1">EPA+DHA n=99</th>
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1"><italic toggle="yes">P</italic> value</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Percent change, median [IQR]</th>
                        <th align="left" rowspan="1" colspan="1">Percent change, median [IQR]</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Hypertensive</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fatty</td>
                        <td align="left" rowspan="1" colspan="1">2.7 [−10.1 to 14.5]</td>
                        <td align="left" rowspan="1" colspan="1">0.81 [−9.2 to 23.7]</td>
                        <td align="left" rowspan="1" colspan="1">0.45</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fibrous</td>
                        <td align="left" rowspan="1" colspan="1">3.6 [−10.6 to 17.2]</td>
                        <td align="left" rowspan="1" colspan="1">1.2 [−10.5 to 15.5]</td>
                        <td align="left" rowspan="1" colspan="1">0.58</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Noncalcified</td>
                        <td align="left" rowspan="1" colspan="1">2.5 [−6.9 to 13.3]</td>
                        <td align="left" rowspan="1" colspan="1">−1.2 [−10.1 to 15.2]</td>
                        <td align="left" rowspan="1" colspan="1">0.68</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Calcified</td>
                        <td align="left" rowspan="1" colspan="1">47.4 [3.1–146.8]</td>
                        <td align="left" rowspan="1" colspan="1">51.4 [2.4–139.6]</td>
                        <td align="left" rowspan="1" colspan="1">0.98</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total</td>
                        <td align="left" rowspan="1" colspan="1">8.3 [−4.2 to 25.1]</td>
                        <td align="left" rowspan="1" colspan="1">7.7 [−2.0 to 20.9]</td>
                        <td align="left" rowspan="1" colspan="1">0.89</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38796-ntgp-0011">
                    <fn id="jah38796-note-0020">
                      <p>BP indicates blood pressure; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; and IQR, interquartile range.</p>
                    </fn>
                    <fn id="jah38796-note-0021">
                      <label>*</label>
                      <p>Within‐group <italic toggle="yes">P</italic> value=0.012.</p>
                    </fn>
                    <fn id="jah38796-note-0022">
                      <label>
                        <sup>†</sup>
                      </label>
                      <p>Within‐group <italic toggle="yes">P</italic> value=0.092.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec sec-type="discussion" id="jah38796-sec-0024">
              <title>DISCUSSION</title>
              <sec id="jah38796-sec-0025">
                <title>Predictors of Regression of Coronary Fatty Plaque: Triglyceride Reduction</title>
                <p>Assessing factors associated with plaque volume and composition has significant prognostic implications. Several studies with CCTA have shown that a higher volume of noncalcified plaque and total plaque is associated with higher rates of cardiac death, MI, and coronary revascularization<xref rid="jah38796-bib-0004" ref-type="bibr"><sup>4</sup></xref> and higher rates of acute coronary syndrome.<xref rid="jah38796-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="jah38796-bib-0006" ref-type="bibr"><sup>6</sup></xref> Furthermore, progression of plaque atheroma volume measured by intravascular ultrasound is an independent predictor of a composite of cardiac death, MI, and coronary revascularization (<italic toggle="yes">P</italic>&lt;0.002), and regression is associated with fewer events.<xref rid="jah38796-bib-0003" ref-type="bibr"><sup>3</sup></xref> Because fatty plaque is more prone to rupture and lead to thrombosis and acute coronary syndrome than fibrous or calcified plaque,<xref rid="jah38796-bib-0009" ref-type="bibr"><sup>9</sup></xref> we examined fatty plaque separately. In the current trial of patients with CAD taking optimal statin therapy and mean LDL‐C &lt;2.07 mmol/L (80 mg/dL), those with regression of fatty plaque had significantly fewer cardiovascular events and significantly lower triglyceride levels at 30 months. This reduction in triglyceride level likely represents treatment effect from EPA+DHA added to statins and was positively and significantly correlated with reduction in coronary fatty plaque (<italic toggle="yes">r</italic>=0.135 [<italic toggle="yes">P</italic>=0.036]). These findings suggest that plaque composition and regression of fatty plaque predict cardiovascular events and support the potential clinical importance of regression of coronary plaque volume. To our knowledge, the current study is the first to report on coronary fatty plaque by CCTA separately from other plaque types.</p>
                <p>A systematic review and meta‐regression analysis of randomized controlled trials reported on the association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid‐lowering therapeutic classes.<xref rid="jah38796-bib-0032" ref-type="bibr"><sup>32</sup></xref> The meta‐regression predicted that lowering triglyceride levels to 0.79 mmol/L (70 mg/dL) (1 mmol/L lower than average baseline triglycerides in the trials included) would have reduced events by 16%, assuming a linear relationship between triglyceride reduction and events at lower triglyceride levels. Taken together, the current findings suggest that in the setting of optimal statin treatment with LDL‐C &lt;2.07 mmol/L (80 mg/dL) and low high‐sensitivity CRP, a reduction in triglyceride level from a level usually considered to be in the normal range is associated with regression of fatty plaque volume, which, in turn, is associated with a reduction in cardiovascular events.</p>
                <p>Prior studies examining the relationship between triglyceride levels and regression or progression of coronary plaque have been limited. A meta‐analysis of 4957 patients with CAD from 9 clinical trials reported on the relationship between achieved triglyceride levels and non–HDL‐C with change in coronary atheroma volume using intravascular ultrasound to measure coronary atheroma volume.<xref rid="jah38796-bib-0033" ref-type="bibr"><sup>33</sup></xref> The rate of atheroma progression started to increase as triglyceride levels increased &gt;1.24 mmol/L (110 mg/dL) in the setting of LDL‐C &lt;1.81 mmol/L (70 mg/dL) (<italic toggle="yes">P</italic>&lt;0.001).<xref rid="jah38796-bib-0033" ref-type="bibr"><sup>33</sup></xref> In the current study, plaque regression occurred with a median 14.9% reduction in triglyceride level from a baseline median of 1.35 to 1.22 mmol/L (120–108 mg/dL) in the setting of baseline mean LDL‐C &lt;2.07 mmol/L (80 mg/dL). This decrease in triglycerides was the only predictor of change in fatty plaque among the lipids and suggests that the reduction in triglycerides may have contributed to plaque regression. It is important to note that the median baseline level of triglycerides was already &lt;1.69 mmol/L (150 mg/dL), which is the current recommended goal by the American Heart Association/American College of Cardiology.<xref rid="jah38796-bib-0034" ref-type="bibr"><sup>34</sup></xref> The current finding suggests that lower levels of triglycerides than currently recommended may be beneficial.</p>
              </sec>
              <sec id="jah38796-sec-0026">
                <title>Baseline Predictors of Fatty Plaque Regression</title>
                <p>We also examined baseline predictors of coronary fatty plaque regression at 30 months. Both non–HDL‐C level &lt;2.59 mmol/L and systolic BP &lt;125 mm Hg were significant independent predictors. Of 9361 patients in SPRINT (Systolic Blood Pressure Intervention Trial), those randomized to intensive BP lowering had a significant reduction in mortality and cardiovascular events compared with the usual care group.<xref rid="jah38796-bib-0035" ref-type="bibr"><sup>35</sup></xref> On the basis of these results, the recommended systolic BP level was lowered from 140 mm Hg to 130 mm Hg.<xref rid="jah38796-bib-0036" ref-type="bibr"><sup>36</sup></xref>, <xref rid="jah38796-bib-0037" ref-type="bibr"><sup>37</sup></xref> The benefit of SBP &lt;125 mm Hg associated with regression of coronary plaque in the current report may be one explanation for lower CVD events in SPRINT.</p>
                <p>The current findings also report that baseline non–HDL‐C &lt;2.59 mmol/L was an independent predictor of fatty plaque regression and a more important predictor than baseline levels of LDL‐C, triglycerides, or remnant cholesterol. Non–HDL‐C is total cholesterol minus HDL‐C, which is the sum of very low‐density lipoprotein cholesterol, intermediate‐density lipoprotein cholesterol, and LDL‐C. Therefore, non–HDL‐C includes the cholesterol in all of the atherogenic apolipoprotein B–containing lipoproteins: triglyceride‐enriched lipoproteins, chylomicrons, chylomicron remnants, very low‐density lipoprotein and very low‐density lipoprotein remnants, intermediate‐density lipoprotein, LDL, and lipoprotein (a), and this may explain the greater predictive value of non–HDL‐C compared with LDL‐C. Elevated levels of non–HDL‐C have been reported to be predictive of CVD and CVD mortality, similar to apolipoprotein B and as good as, or better than, that of LDL‐C.<xref rid="jah38796-bib-0038" ref-type="bibr"><sup>38</sup></xref>, <xref rid="jah38796-bib-0039" ref-type="bibr"><sup>39</sup></xref>, <xref rid="jah38796-bib-0040" ref-type="bibr"><sup>40</sup></xref>, <xref rid="jah38796-bib-0041" ref-type="bibr"><sup>41</sup></xref> During a median follow‐up of 6.1 years in 302 430 individuals without CVD from 68 long‐term prospective studies in North America and Europe, the HR for nonfatal MI and coronary heart disease death for triglycerides was 1.37 (95% CI, 1.31–1.42) after adjustment for nonlipid risk factors.<xref rid="jah38796-bib-0042" ref-type="bibr"><sup>42</sup></xref> However, the HR for triglycerides was reduced to 0.99 (95% CI, 0.94–1.05) after further adjustment for HDL‐C and non–HDL‐C. After adjustment for nonlipid risk factors, the HR for coronary heart disease with non–HDL‐C was 1.56 (95% CI, 1.47–1.66) and remained significant at 1.50 (95% CI, 1.39–1.61) after adjustment for HDL‐C and log triglyceride. The better prediction of coronary heart disease risk and future cardiovascular events with non–HDL‐C than LDL‐C or triglyceride level is probably due to the inclusion of all apolipoprotein B–containing lipoproteins in non–HDL‐C.</p>
              </sec>
              <sec id="jah38796-sec-0027">
                <title>Outcomes in Normotensive Compared With Hypertensive Patients</title>
                <p>When stratified by BP status, important findings emerge. Normotensive patients taking EPA+DHA had regression of noncalcified plaque compared with control, whereas there was no difference in hypertensive patients. Moreover, compared with patients taking control, normotensive patients taking EPA+DHA had a significant reduction in neutrophil count and NLR, whereas hypertensive patients did not. Furthermore, the reduction in triglycerides correlated with the change in noncalcified plaque in normotensive patients. These findings suggest that the effect of EPA+DHA supplementation is modified by hypertension status, and normotensive patients may have greater benefit. When baseline characteristics of the regressors and progressors were compared, the progressors had significantly higher levels of WBC and neutrophil counts, markers of inflammation; thus, these findings suggest that progressors had a higher level of inflammation at baseline. The total WBC count has been reported to predict the incidence of CAD and mortality in patients without CAD and mortality in patients with CAD.<xref rid="jah38796-bib-0043" ref-type="bibr"><sup>43</sup></xref> In a meta‐analysis of 7 large studies including 5337 patients without CAD, a 1.4‐fold increased risk of CAD (95% CI, 1.3–1.5) was observed with a high baseline WBC count, comparable to that of high‐sensitivity CRP (relative risk, 1.45 [95% CI, 1.25–1.68]).<xref rid="jah38796-bib-0044" ref-type="bibr"><sup>44</sup></xref>, <xref rid="jah38796-bib-0045" ref-type="bibr"><sup>45</sup></xref> Whether higher levels of inflammation lessen response to omega‐3 fatty acid supplementation should be examined in future studies. If this were the case, higher levels of omega‐3 fatty acid supplementation should be examined to determine whether higher levels would improve outcome.</p>
                <p>The current finding of a benefit on “NLR” in normotensive patients lends further support to a role of inflammation. Inflammation has been established to play a role in the development of cardiovascular events through its involvement in the pathogenesis and progression of atherosclerosis via various possible mechanisms.<xref rid="jah38796-bib-0046" ref-type="bibr"><sup>46</sup></xref> The NLR reflects a dynamic relationship between neutrophils and lymphocytes and is a sensitive marker of inflammation.<xref rid="jah38796-bib-0047" ref-type="bibr"><sup>47</sup></xref> Neutrophils secrete proinflammatory mediators that may cause vascular wall degeneration,<xref rid="jah38796-bib-0048" ref-type="bibr"><sup>48</sup></xref> while lymphocytes regulate the inflammatory response through T‐regulatory lymphocytes and have an antiatherosclerotic effect.<xref rid="jah38796-bib-0049" ref-type="bibr"><sup>49</sup></xref>
</p>
                <p>NLR is inexpensive and readily available from a complete blood cell count. It positively correlates with CRP levels<xref rid="jah38796-bib-0050" ref-type="bibr"><sup>50</sup></xref>, <xref rid="jah38796-bib-0051" ref-type="bibr"><sup>51</sup></xref> and could serve as a potential surrogate marker for CRP.<xref rid="jah38796-bib-0051" ref-type="bibr"><sup>51</sup></xref> In certain instances, NLR is better at predicting outcomes, such as bacteremia or the severity of community‐acquired pneumonia, than CRP.<xref rid="jah38796-bib-0052" ref-type="bibr"><sup>52</sup></xref>, <xref rid="jah38796-bib-0053" ref-type="bibr"><sup>53</sup></xref> NLR also has advantages as it is not influenced by physiological conditions such as dehydration and exercise, conditions that affect the absolute numbers of individual cell types.<xref rid="jah38796-bib-0054" ref-type="bibr"><sup>54</sup></xref>
</p>
                <p>In a systematic review and meta‐analysis, NLR has been found to be significantly associated with CVD outcomes including CAD, acute coronary syndrome, stroke, and composite cardiovascular events.<xref rid="jah38796-bib-0055" ref-type="bibr"><sup>55</sup></xref> Moreover, NLR is independently and significantly associated with an increased risk of all‐cause mortality, cardiovascular mortality, and other mortality (but not cancer mortality) and is thus considered a strong and independent risk indicator for mortality in the elderly population.<xref rid="jah38796-bib-0056" ref-type="bibr"><sup>56</sup></xref> Therefore, the beneficial effect of EPA+DHA on NLR in the current report would potentially predict a beneficial effect on CVD outcomes.</p>
                <p>Potential mechanisms for the lower response to omega‐3 fatty acids in hypertensive patients in the current report could be due to the association of hypertension with endothelial dysfunction, which is involved in the initiation and development of vascular inflammation and characterized by vasoconstriction, cell proliferation, and shifting toward a proinflammatory and prothrombotic state, leading to increased cardiovascular risk and atherosclerosis.<xref rid="jah38796-bib-0057" ref-type="bibr"><sup>57</sup></xref> A basic study that lends support to potential differential findings by BP status is that of Ning et al,<xref rid="jah38796-bib-0058" ref-type="bibr"><sup>58</sup></xref> who generated hypertension in Watanabe heritable hyperlipidemic (WHHL) rabbits by surgically removing 1 kidney and partially ligating the other renal artery. Forty percent of the small arteries and arterioles in hypertensive WHHL rabbits were completely occluded compared with 5% in normotensive WHHL rabbits.<xref rid="jah38796-bib-0058" ref-type="bibr"><sup>58</sup></xref> Moreover, these coronary lesions in hypertensive WHHL rabbits were accompanied by an increased number of macrophages and smooth muscle cells compared with normotensive WHHL rabbits. Lipid levels were similar in both rabbits. Compared with the normotensive WHHL group, aortic intimal lesions of hypertensive WHHL rabbits were 1.6‐fold higher in the aortic arch and 1.4‐fold higher in the thoracic and abdominal aorta with an 8.5‐fold increase in aortic macrophages (<italic toggle="yes">P</italic>&lt;0.01) and a higher frequency of intraplaque hemorrhage and vulnerable plaques.<xref rid="jah38796-bib-0058" ref-type="bibr"><sup>58</sup></xref> Five of 7 hypertensive WHHL rabbits had transmural MIs compared with none of the 7 normotensive WHHL rabbits; all hypertensive WHHL rabbits died within 34 to 56 weeks compared with no normotensive WHHL rabbits. These results indicate that hypertension induced in WHHL rabbits may not only enhance the development of atherosclerosis but also destabilize the plaques and increase cardiac death compared with normotensive rabbits.<xref rid="jah38796-bib-0058" ref-type="bibr"><sup>58</sup></xref>
</p>
              </sec>
              <sec id="jah38796-sec-0028">
                <title>Strengths and Limitations</title>
                <p>The strengths of the current study include the use of CCTA to measure atherosclerotic plaque subtypes, the randomization to high‐dose EPA+DHA, 30‐month follow‐up, and the significant reduction in cardiovascular events noted in those with regression of coronary fatty plaque. All CCTA results were read by a core team that allows consistency in measurement. Generalizability is limited to patients with clinical CAD.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="jah38796-sec-0029">
              <title>CONCLUSIONS</title>
              <p>Patients with regression of coronary fatty plaque had 4‐fold fewer cardiac events. Triglyceride reduction with EPA+DHA at 30 months correlated positively with coronary fatty plaque regression. Baseline levels of non–HDL‐C level &lt;2.59 mmol/L and systolic BP &lt;125 mm Hg were significant independent predictors of coronary fatty plaque regression. Normotensive patients taking EPA+DHA compared with control had regression of noncalcified coronary plaque, which correlated with a decrease in triglyceride level; they also had a significant decrease in neutrophil and WBC count and NLR, all markers of inflammation. In contrast, hypertensive patients had no change in coronary plaque or NLR. Thus, normotensive patients show greater benefit than hypertensive patients, which may be due to lower levels of inflammation. Future studies should examine the role of EPA+DHA in inflammation further. Taken together, the current results suggest that SBP &lt;125 mm Hg and non–HDL‐C &lt;2.59 mmol/L would be predicted to prevent progression of fatty plaque and potentially lead to regression, thus possibly decreasing the risk of CVD events and reducing residual risk in statin‐treated patients. The study highlights the importance of maintaining optimal levels of triglycerides, non–HDL‐C, and systolic BP, in addition to guideline‐recommended LDL‐C levels, to reduce cardiac events and regress coronary fatty plaque.</p>
            </sec>
            <sec id="jah38796-sec-0031">
              <title>Sources of Funding</title>
              <p>This work was supported by the National Institutes of Health Specialized Center of Clinically Oriented Research program grant to Dr Welty (P50 HL083813) and by the Harvard Clinical and Translational Science Center Award (NIH UL1 TR001102).</p>
            </sec>
            <sec id="jah38796-sec-0032">
              <title>Disclosures</title>
              <p>None.</p>
            </sec>
          </body>
          <back>
            <ack id="jah38796-sec-0030">
              <title>Acknowledgments</title>
              <p>The authors thank the study patients for participating in the study. FKW designed the trial, obtained funding, enrolled patients, acquired data, and drafted the article. FKW, AM, and AAA had full access to all of the data in the study and take responsibility for the integrity of the data. AM and AAA take responsibility for the accuracy of the data analysis. FW, TE, AM, RD, AAA, AA, and EH contributed to interpretation of data. All authors critically revised the article, gave final approval, and agree to be accountable for all aspects of the work ensuring integrity and accuracy.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah38796-bibl-0001">
              <title>References</title>
              <ref id="jah38796-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0001"><string-name><surname>Sampson</surname><given-names>UK</given-names></string-name>, <string-name><surname>Fazio</surname><given-names>S</given-names></string-name>, <string-name><surname>Linton</surname><given-names>MF</given-names></string-name>. <article-title>Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges</article-title>. <source>Curr Atheroscler Rep</source>. <year>2012</year>;<volume>14</volume>:<fpage>1</fpage>–<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11883-011-0219-7</pub-id>
<pub-id pub-id-type="pmid">22102062</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0002"><string-name><surname>Bayturan</surname><given-names>O</given-names></string-name>, <string-name><surname>Kapadia</surname><given-names>S</given-names></string-name>, <string-name><surname>Nicholls</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Tuzcu</surname><given-names>EM</given-names></string-name>, <string-name><surname>Shao</surname><given-names>M</given-names></string-name>, <string-name><surname>Uno</surname><given-names>K</given-names></string-name>, <string-name><surname>Shreevatsa</surname><given-names>A</given-names></string-name>, <string-name><surname>Lavoie</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Wolski</surname><given-names>K</given-names></string-name>, <string-name><surname>Schoenhagen</surname><given-names>P</given-names></string-name>, et al. <article-title>Clinical predictors of plaque progression despite very low levels of low‐density lipoprotein cholesterol</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>55</volume>:<fpage>2736</fpage>–<lpage>2742</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2010.01.050</pub-id>
<pub-id pub-id-type="pmid">20538166</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0003"><string-name><surname>Nicholls</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>A</given-names></string-name>, <string-name><surname>Wolski</surname><given-names>K</given-names></string-name>, <string-name><surname>Hu</surname><given-names>B</given-names></string-name>, <string-name><surname>Bayturan</surname><given-names>O</given-names></string-name>, <string-name><surname>Lavoie</surname><given-names>A</given-names></string-name>, <string-name><surname>Uno</surname><given-names>K</given-names></string-name>, <string-name><surname>Tuzcu</surname><given-names>EM</given-names></string-name>, <string-name><surname>Nissen</surname><given-names>SE</given-names></string-name>. <article-title>Intravascular ultrasound‐derived measures of coronary atherosclerotic plaque burden and clinical outcome</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>55</volume>:<fpage>2399</fpage>–<lpage>2407</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2010.02.026</pub-id>
<pub-id pub-id-type="pmid">20488313</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0004"><string-name><surname>Nadjiri</surname><given-names>J</given-names></string-name>, <string-name><surname>Hausleiter</surname><given-names>J</given-names></string-name>, <string-name><surname>Jähnichen</surname><given-names>C</given-names></string-name>, <string-name><surname>Will</surname><given-names>A</given-names></string-name>, <string-name><surname>Hendrich</surname><given-names>E</given-names></string-name>, <string-name><surname>Martinoff</surname><given-names>S</given-names></string-name>, <string-name><surname>Hadamitzky</surname><given-names>M</given-names></string-name>. <article-title>Incremental prognostic value of quantitative plaque assessment in coronary CT angiography during 5 years of follow up</article-title>. <source>J Cardiovasc Comput Tomogr</source>. <year>2016</year>;<volume>10</volume>:<fpage>97</fpage>–<lpage>104</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcct.2016.01.007</pub-id>
<pub-id pub-id-type="pmid">26837235</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0005"><string-name><surname>Versteylen</surname><given-names>MO</given-names></string-name>, <string-name><surname>Kietselaer</surname><given-names>BL</given-names></string-name>, <string-name><surname>Dagnelie</surname><given-names>PC</given-names></string-name>, <string-name><surname>Joosen</surname><given-names>IA</given-names></string-name>, <string-name><surname>Dedic</surname><given-names>A</given-names></string-name>, <string-name><surname>Raaijmakers</surname><given-names>RH</given-names></string-name>, <string-name><surname>Wildberger</surname><given-names>JE</given-names></string-name>, <string-name><surname>Nieman</surname><given-names>K</given-names></string-name>, <string-name><surname>Crijns</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Niessen</surname><given-names>WJ</given-names></string-name>, et al. <article-title>Additive value of semiautomated quantification of coronary artery disease using cardiac computed tomographic angiography to predict future acute coronary syndrome</article-title>. <source>J Am Coll Cardiol</source>. <year>2013</year>;<volume>61</volume>:<fpage>2296</fpage>–<lpage>2305</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2013.02.065</pub-id>
<pub-id pub-id-type="pmid">23562925</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0006"><string-name><surname>Motoyama</surname><given-names>S</given-names></string-name>, <string-name><surname>Sarai</surname><given-names>M</given-names></string-name>, <string-name><surname>Harigaya</surname><given-names>H</given-names></string-name>, <string-name><surname>Anno</surname><given-names>H</given-names></string-name>, <string-name><surname>Inoue</surname><given-names>K</given-names></string-name>, <string-name><surname>Hara</surname><given-names>T</given-names></string-name>, <string-name><surname>Naruse</surname><given-names>H</given-names></string-name>, <string-name><surname>Ishii</surname><given-names>J</given-names></string-name>, <string-name><surname>Hishida</surname><given-names>H</given-names></string-name>, <string-name><surname>Wong</surname><given-names>ND</given-names></string-name>, et al. <article-title>Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>54</volume>:<fpage>49</fpage>–<lpage>57</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2009.02.068</pub-id>
<pub-id pub-id-type="pmid">19555840</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0007"><string-name><surname>Alfaddagh</surname><given-names>A</given-names></string-name>, <string-name><surname>Elajami</surname><given-names>TK</given-names></string-name>, <string-name><surname>Saleh</surname><given-names>M</given-names></string-name>, <string-name><surname>Mohebali</surname><given-names>D</given-names></string-name>, <string-name><surname>Bistrian</surname><given-names>BR</given-names></string-name>, <string-name><surname>Welty</surname><given-names>FK</given-names></string-name>. <article-title>An omega‐3 fatty acid plasma index ≥4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment</article-title>. <source>Atherosclerosis</source>. <year>2019</year>;<volume>285</volume>:<fpage>153</fpage>–<lpage>162</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2019.04.213</pub-id>
<pub-id pub-id-type="pmid">31055222</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0008"><string-name><surname>Welty</surname><given-names>FK</given-names></string-name>, <string-name><surname>Schulte</surname><given-names>F</given-names></string-name>, <string-name><surname>Alfaddagh</surname><given-names>A</given-names></string-name>, <string-name><surname>Elajami</surname><given-names>TK</given-names></string-name>, <string-name><surname>Bistrian</surname><given-names>BR</given-names></string-name>, <string-name><surname>Hardt</surname><given-names>M</given-names></string-name>. <article-title>Regression of human coronary artery plaque is associated with a high ratio of (18‐hydroxy‐eicosapentaenoic acid+Resolvin E1) to leukotriene B4</article-title>. <source>FASEB J</source>. <year>2021</year>;<volume>35</volume>:<elocation-id>e21448</elocation-id>. doi: <pub-id pub-id-type="doi">10.1096/fj.202002471R</pub-id><pub-id pub-id-type="pmid">33749913</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0009"><string-name><surname>van der Wal</surname><given-names>AC</given-names></string-name>, <string-name><surname>Becker</surname><given-names>AE</given-names></string-name>. <article-title>Atherosclerotic plaque rupture—pathologic basis of plaque stability and instability</article-title>. <source>Cardiovasc Res</source>. <year>1999</year>;<volume>41</volume>:<fpage>334</fpage>–<lpage>344</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0008-6363(98)00276-4</pub-id>
<pub-id pub-id-type="pmid">10341833</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0010"><string-name><surname>Obaid</surname><given-names>DR</given-names></string-name>, <string-name><surname>Calvert</surname><given-names>PA</given-names></string-name>, <string-name><surname>Gopalan</surname><given-names>D</given-names></string-name>, <string-name><surname>Parker</surname><given-names>RA</given-names></string-name>, <string-name><surname>West</surname><given-names>NEJ</given-names></string-name>, <string-name><surname>Goddard</surname><given-names>M</given-names></string-name>, <string-name><surname>Rudd</surname><given-names>JHF</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>MR</given-names></string-name>. <article-title>Dual‐energy computed tomography imaging to determine atherosclerotic plaque composition: a prospective study with tissue validation</article-title>. <source>J Cardiovasc Comput Tomogr</source>. <year>2014</year>;<volume>8</volume>:<fpage>230</fpage>–<lpage>237</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcct.2014.04.007</pub-id>
<pub-id pub-id-type="pmid">24939072</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0011"><string-name><surname>Obaid</surname><given-names>DR</given-names></string-name>, <string-name><surname>Calvert</surname><given-names>PA</given-names></string-name>, <string-name><surname>Gopalan</surname><given-names>D</given-names></string-name>, <string-name><surname>Parker</surname><given-names>RA</given-names></string-name>, <string-name><surname>Hoole</surname><given-names>SP</given-names></string-name>, <string-name><surname>West</surname><given-names>NEJ</given-names></string-name>, <string-name><surname>Goddard</surname><given-names>M</given-names></string-name>, <string-name><surname>Rudd</surname><given-names>JHF</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>MR</given-names></string-name>. <article-title>Atherosclerotic plaque composition and classification identified by coronary computed tomography: assessment of computed tomography‐generated plaque maps compared with virtual histology intravascular ultrasound and histology</article-title>. <source>Circ Cardiovasc Imaging</source>. <year>2013</year>;<volume>6</volume>:<fpage>655</fpage>–<lpage>664</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCIMAGING.112.000250</pub-id>
<pub-id pub-id-type="pmid">23960215</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0012"><string-name><surname>Rinehart</surname><given-names>S</given-names></string-name>, <string-name><surname>Vazquez</surname><given-names>G</given-names></string-name>, <string-name><surname>Qian</surname><given-names>Z</given-names></string-name>, <string-name><surname>Murrieta</surname><given-names>L</given-names></string-name>, <string-name><surname>Christian</surname><given-names>K</given-names></string-name>, <string-name><surname>Voros</surname><given-names>S</given-names></string-name>. <article-title>Quantitative measurements of coronary arterial stenosis, plaque geometry, and composition are highly reproducible with a standardized coronary arterial computed tomographic approach in high‐quality CT datasets</article-title>. <source>J Cardiovasc Comput Tomogr</source>. <year>2011</year>;<volume>5</volume>:<fpage>35</fpage>–<lpage>43</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcct.2010.09.006</pub-id>
<pub-id pub-id-type="pmid">21131252</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0013"><string-name><surname>Sandfort</surname><given-names>V</given-names></string-name>, <string-name><surname>Lima</surname><given-names>JAC</given-names></string-name>, <string-name><surname>Bluemke</surname><given-names>DA</given-names></string-name>. <article-title>Noninvasive imaging of atherosclerotic plaque progression: status of coronary computed tomography angiography</article-title>. <source>Circ Cardiovasc Imaging</source>. <year>2015</year>;<volume>8</volume>:<elocation-id>e003316</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/CIRCIMAGING.115.003316</pub-id><pub-id pub-id-type="pmid">26156016</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0014"><string-name><surname>Burgstahler</surname><given-names>C</given-names></string-name>, <string-name><surname>Reimann</surname><given-names>A</given-names></string-name>, <string-name><surname>Beck</surname><given-names>T</given-names></string-name>, <string-name><surname>Kuettner</surname><given-names>A</given-names></string-name>, <string-name><surname>Baumann</surname><given-names>D</given-names></string-name>, <string-name><surname>Heuschmid</surname><given-names>M</given-names></string-name>, <string-name><surname>Brodoefel</surname><given-names>H</given-names></string-name>, <string-name><surname>Claussen</surname><given-names>CD</given-names></string-name>, <string-name><surname>Kopp</surname><given-names>AF</given-names></string-name>, <string-name><surname>Schroeder</surname><given-names>S</given-names></string-name>. <article-title>Influence of a lipid‐lowering therapy on calcified and noncalcified coronary plaques monitored by multislice detector computed tomography: results of the new age II pilot study</article-title>. <source>Invest Radiol</source>. <year>2007</year>;<volume>42</volume>:<fpage>189</fpage>–<lpage>195</lpage>. doi: <pub-id pub-id-type="doi">10.1097/01.rli.0000254408.96355.85</pub-id>
<pub-id pub-id-type="pmid">17287649</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0015"><string-name><surname>Hoffmann</surname><given-names>H</given-names></string-name>, <string-name><surname>Frieler</surname><given-names>K</given-names></string-name>, <string-name><surname>Schlattmann</surname><given-names>P</given-names></string-name>, <string-name><surname>Hamm</surname><given-names>B</given-names></string-name>, <string-name><surname>Dewey</surname><given-names>M</given-names></string-name>. <article-title>Influence of statin treatment on coronary atherosclerosis visualised using multidetector computed tomography</article-title>. <source>Eur Radiol</source>. <year>2010</year>;<volume>20</volume>:<fpage>2824</fpage>–<lpage>2833</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00330-010-1880-x</pub-id>
<pub-id pub-id-type="pmid">20640900</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0016"><string-name><surname>Inoue</surname><given-names>K</given-names></string-name>, <string-name><surname>Motoyama</surname><given-names>S</given-names></string-name>, <string-name><surname>Sarai</surname><given-names>M</given-names></string-name>, <string-name><surname>Sato</surname><given-names>T</given-names></string-name>, <string-name><surname>Harigaya</surname><given-names>H</given-names></string-name>, <string-name><surname>Hara</surname><given-names>T</given-names></string-name>, <string-name><surname>Sanda</surname><given-names>Y</given-names></string-name>, <string-name><surname>Anno</surname><given-names>H</given-names></string-name>, <string-name><surname>Kondo</surname><given-names>T</given-names></string-name>, <string-name><surname>Wong</surname><given-names>ND</given-names></string-name>, et al. <article-title>Serial coronary CT angiography‐verified changes in plaque characteristics as an end point: evaluation of effect of statin intervention</article-title>. <source>JACC Cardiovasc Imaging</source>. <year>2010</year>;<volume>3</volume>:<fpage>691</fpage>–<lpage>698</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcmg.2010.04.011</pub-id>
<pub-id pub-id-type="pmid">20633846</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0017"><string-name><surname>Shimojima</surname><given-names>M</given-names></string-name>, <string-name><surname>Kawashiri</surname><given-names>M</given-names></string-name>, <string-name><surname>Nitta</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yoshida</surname><given-names>T</given-names></string-name>, <string-name><surname>Katsuda</surname><given-names>S</given-names></string-name>, <string-name><surname>Kaku</surname><given-names>B</given-names></string-name>, <string-name><surname>Taguchi</surname><given-names>T</given-names></string-name>, <string-name><surname>Hasegawa</surname><given-names>A</given-names></string-name>, <string-name><surname>Konno</surname><given-names>T</given-names></string-name>, <string-name><surname>Hayashi</surname><given-names>K</given-names></string-name>, et al. <article-title>Rapid changes in plaque composition and morphology after intensive lipid lowering therapy: study with serial coronary CT angiography</article-title>. <source>Am J Cardiovasc Dis</source>. <year>2012</year>;<volume>2</volume>:<fpage>84</fpage>–<lpage>88</lpage>.<pub-id pub-id-type="pmid">22720196</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0018"><string-name><surname>Zeb</surname><given-names>I</given-names></string-name>, <string-name><surname>Li</surname><given-names>D</given-names></string-name>, <string-name><surname>Nasir</surname><given-names>K</given-names></string-name>, <string-name><surname>Malpeso</surname><given-names>J</given-names></string-name>, <string-name><surname>Batool</surname><given-names>A</given-names></string-name>, <string-name><surname>Flores</surname><given-names>F</given-names></string-name>, <string-name><surname>Dailing</surname><given-names>C</given-names></string-name>, <string-name><surname>Karlsberg</surname><given-names>RP</given-names></string-name>, <string-name><surname>Budoff</surname><given-names>M</given-names></string-name>. <article-title>Effect of statin treatment on coronary plaque progression—a serial coronary CT angiography study</article-title>. <source>Atherosclerosis</source>. <year>2013</year>;<volume>231</volume>:<fpage>198</fpage>–<lpage>204</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2013.08.019</pub-id>
<pub-id pub-id-type="pmid">24267226</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0019"><string-name><surname>Alfaddagh</surname><given-names>A</given-names></string-name>, <string-name><surname>Elajami</surname><given-names>TK</given-names></string-name>, <string-name><surname>Ashfaque</surname><given-names>H</given-names></string-name>, <string-name><surname>Saleh</surname><given-names>M</given-names></string-name>, <string-name><surname>Bistrian</surname><given-names>BR</given-names></string-name>, <string-name><surname>Welty</surname><given-names>FK</given-names></string-name>. <article-title>Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial</article-title>. <source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e006981</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/JAHA.117.006981</pub-id><pub-id pub-id-type="pmid">29246960</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0020"><string-name><surname>Elajami</surname><given-names>TK</given-names></string-name>, <string-name><surname>Alfaddagh</surname><given-names>A</given-names></string-name>, <string-name><surname>Lakshminarayan</surname><given-names>D</given-names></string-name>, <string-name><surname>Soliman</surname><given-names>M</given-names></string-name>, <string-name><surname>Chandnani</surname><given-names>M</given-names></string-name>, <string-name><surname>Welty</surname><given-names>FK</given-names></string-name>. <article-title>Eicosapentaenoic and docosahexaenoic acids attenuate progression of albuminuria in patients with type 2 diabetes mellitus and coronary artery disease</article-title>. <source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e004740</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/JAHA.116.004740</pub-id><pub-id pub-id-type="pmid">28710178</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0021"><string-name><surname>Alfaddagh</surname><given-names>A</given-names></string-name>, <string-name><surname>Elajami</surname><given-names>TK</given-names></string-name>, <string-name><surname>Saleh</surname><given-names>M</given-names></string-name>, <string-name><surname>Elajami</surname><given-names>M</given-names></string-name>, <string-name><surname>Bistrian</surname><given-names>BR</given-names></string-name>, <string-name><surname>Welty</surname><given-names>FK</given-names></string-name>. <article-title>The effect of eicosapentaenoic and docosahexaenoic acids on physical function, exercise and joint replacement in patients with coronary artery disease: a secondary analysis of a randomized clinical trial</article-title>. <source>J Clin Lipidol</source>. <year>2018</year>;<volume>12</volume>:<fpage>937</fpage>–<lpage>947</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacl.2018.03.080</pub-id>
<pub-id pub-id-type="pmid">29752179</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0022"><string-name><surname>Saleh</surname><given-names>M</given-names></string-name>, <string-name><surname>Alfaddagh</surname><given-names>A</given-names></string-name>, <string-name><surname>Elajami</surname><given-names>TK</given-names></string-name>, <string-name><surname>Ashfaque</surname><given-names>H</given-names></string-name>, <string-name><surname>Haj‐Ibrahim</surname><given-names>H</given-names></string-name>, <string-name><surname>Welty</surname><given-names>FK</given-names></string-name>. <article-title>Diastolic blood pressure predicts coronary plaque volume in patients with coronary artery disease</article-title>. <source>Atherosclerosis</source>. <year>2018</year>;<volume>277</volume>:<fpage>34</fpage>–<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2018.07.031</pub-id>
<pub-id pub-id-type="pmid">30170222</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0023"><string-name><surname>Malik</surname><given-names>A</given-names></string-name>, <string-name><surname>Ramadan</surname><given-names>A</given-names></string-name>, <string-name><surname>Vemuri</surname><given-names>B</given-names></string-name>, <string-name><surname>Siddiq</surname><given-names>W</given-names></string-name>, <string-name><surname>Amangurbanova</surname><given-names>M</given-names></string-name>, <string-name><surname>Ali</surname><given-names>A</given-names></string-name>, <string-name><surname>Welty</surname><given-names>FK</given-names></string-name>. <article-title>Ω‐3 ethyl ester results in better cognitive function at 12 and 30 months than control in cognitively healthy subjects with coronary artery disease: a secondary analysis of a randomized clinical trial</article-title>. <source>Am J Clin Nutr</source>. <year>2021</year>;<volume>113</volume>:<fpage>1168</fpage>–<lpage>1176</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ajcn/nqaa420</pub-id>
<pub-id pub-id-type="pmid">33675344</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0024"><string-name><surname>Chedid</surname><given-names>G</given-names></string-name>, <string-name><surname>Malik</surname><given-names>A</given-names></string-name>, <string-name><surname>Amangurbanova</surname><given-names>M</given-names></string-name>, <string-name><surname>Khraishah</surname><given-names>H</given-names></string-name>, <string-name><surname>Welty</surname><given-names>FK</given-names></string-name>. <article-title>Docosahexaenoic acid levels and omega‐3 index, but not eicosapentaenoic acid levels, are associated with improved cognition in cognitively healthy subjects with coronary artery disease</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2023</year>;<volume>43</volume>:<fpage>382</fpage>–<lpage>384</lpage>. doi: <pub-id pub-id-type="doi">10.1161/ATVBAHA.122.318569</pub-id>
<pub-id pub-id-type="pmid">36579646</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0025"><string-name><surname>Hirano</surname><given-names>T</given-names></string-name>, <string-name><surname>Ito</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yoshino</surname><given-names>G</given-names></string-name>. <article-title>Measurement of small dense low‐density lipoprotein particles</article-title>. <source>J Atheroscler Thromb</source>. <year>2005</year>;<volume>12</volume>:<fpage>67</fpage>–<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.5551/jat.12.67</pub-id>
<pub-id pub-id-type="pmid">15942115</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0026"><string-name><surname>Thygesen</surname><given-names>K</given-names></string-name>, <string-name><surname>Alpert</surname><given-names>JS</given-names></string-name>, <string-name><surname>Jaffe</surname><given-names>AS</given-names></string-name>, <string-name><surname>Simoons</surname><given-names>ML</given-names></string-name>, <string-name><surname>Chaitman</surname><given-names>BR</given-names></string-name>, <string-name><surname>White</surname><given-names>HD</given-names></string-name>. <article-title>Writing group on the joint ESC/ACCF/AHA/WHF task force for the universal definition of myocardial infarction. Third universal definition of myocardial infarction</article-title>. <source>Eur Heart J</source>. <year>2012</year>;<volume>33</volume>:<fpage>2551</fpage>–<lpage>2567</lpage>. doi: <pub-id pub-id-type="doi">10.1093/eurheartj/ehs184</pub-id>
<pub-id pub-id-type="pmid">22922414</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0027"><string-name><surname>Khosa</surname><given-names>F</given-names></string-name>, <string-name><surname>Khan</surname><given-names>AN</given-names></string-name>, <string-name><surname>Nasir</surname><given-names>K</given-names></string-name>, <string-name><surname>Bedayat</surname><given-names>A</given-names></string-name>, <string-name><surname>Malik</surname><given-names>Z</given-names></string-name>, <string-name><surname>Jon</surname><given-names>AF</given-names></string-name>, <string-name><surname>Cheema</surname><given-names>AR</given-names></string-name>, <string-name><surname>Clouse</surname><given-names>ME</given-names></string-name>, <string-name><surname>Welty</surname><given-names>FK</given-names></string-name>. <article-title>Comparison of coronary plaque subtypes in male and female patients using 320‐row MDCTA</article-title>. <source>Atherosclerosis</source>. <year>2013</year>;<volume>226</volume>:<fpage>428</fpage>–<lpage>432</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2012.11.033</pub-id>
<pub-id pub-id-type="pmid">23287639</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0028"><string-name><surname>Hauser</surname><given-names>TH</given-names></string-name>, <string-name><surname>Salastekar</surname><given-names>N</given-names></string-name>, <string-name><surname>Schaefer</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Desai</surname><given-names>T</given-names></string-name>, <string-name><surname>Goldfine</surname><given-names>HL</given-names></string-name>, <string-name><surname>Fowler</surname><given-names>KM</given-names></string-name>, <string-name><surname>Weber</surname><given-names>GM</given-names></string-name>, <string-name><surname>Welty</surname><given-names>F</given-names></string-name>, <string-name><surname>Clouse</surname><given-names>M</given-names></string-name>, <string-name><surname>Shoelson</surname><given-names>SE</given-names></string-name>, et al. <article-title>Targeting inflammation using Salsalate in cardiovascular disease (TINSAL‐CVD) study team. Effect of targeting inflammation with Salsalate: the TINSAL‐CVD randomized clinical trial on progression of coronary plaque in overweight and obese patients using statins</article-title>. <source>JAMA Cardiol</source>. <year>2016</year>;<volume>1</volume>:<fpage>413</fpage>–<lpage>423</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamacardio.2016.0605</pub-id>
<pub-id pub-id-type="pmid">27438317</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0029"><string-name><surname>Brodoefel</surname><given-names>H</given-names></string-name>, <string-name><surname>Burgstahler</surname><given-names>C</given-names></string-name>, <string-name><surname>Sabir</surname><given-names>A</given-names></string-name>, <string-name><surname>Yam</surname><given-names>C‐S</given-names></string-name>, <string-name><surname>Khosa</surname><given-names>F</given-names></string-name>, <string-name><surname>Claussen</surname><given-names>CD</given-names></string-name>, <string-name><surname>Clouse</surname><given-names>ME</given-names></string-name>. <article-title>Coronary plaque quantification by voxel analysis: dual‐source MDCT angiography versus intravascular sonography</article-title>. <source>Am J Roentgenol</source>. <year>2009</year>;<volume>192</volume>:<fpage>W84</fpage>–<lpage>W89</lpage>. doi: <pub-id pub-id-type="doi">10.2214/AJR.08.1381</pub-id>
<pub-id pub-id-type="pmid">19234244</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0030"><string-name><surname>Voros</surname><given-names>S</given-names></string-name>, <string-name><surname>Rinehart</surname><given-names>S</given-names></string-name>, <string-name><surname>Qian</surname><given-names>Z</given-names></string-name>, <string-name><surname>Joshi</surname><given-names>P</given-names></string-name>, <string-name><surname>Vazquez</surname><given-names>G</given-names></string-name>, <string-name><surname>Fischer</surname><given-names>C</given-names></string-name>, <string-name><surname>Belur</surname><given-names>P</given-names></string-name>, <string-name><surname>Hulten</surname><given-names>E</given-names></string-name>, <string-name><surname>Villines</surname><given-names>TC</given-names></string-name>. <article-title>Coronary atherosclerosis imaging by coronary CT angiography: current status, correlation with intravascular interrogation and meta‐analysis</article-title>. <source>JACC Cardiovasc Imaging</source>. <year>2011</year>;<volume>4</volume>:<fpage>537</fpage>–<lpage>548</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcmg.2011.03.006</pub-id>
<pub-id pub-id-type="pmid">21565743</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0031"><string-name><surname>Brodoefel</surname><given-names>H</given-names></string-name>, <string-name><surname>Burgstahler</surname><given-names>C</given-names></string-name>, <string-name><surname>Heuschmid</surname><given-names>M</given-names></string-name>, <string-name><surname>Reimann</surname><given-names>A</given-names></string-name>, <string-name><surname>Khosa</surname><given-names>F</given-names></string-name>, <string-name><surname>Kopp</surname><given-names>A</given-names></string-name>, <string-name><surname>Schroeder</surname><given-names>S</given-names></string-name>, <string-name><surname>Claussen</surname><given-names>CD</given-names></string-name>, <string-name><surname>Clouse</surname><given-names>ME</given-names></string-name>. <article-title>Accuracy of dual‐source CT in the characterisation of non‐calcified plaque: use of a colour‐coded analysis compared with virtual histology intravascular ultrasound</article-title>. <source>Br J Radiol</source>. <year>2009</year>;<volume>82</volume>:<fpage>805</fpage>–<lpage>812</lpage>. doi: <pub-id pub-id-type="doi">10.1259/bjr/35768497</pub-id>
<pub-id pub-id-type="pmid">19332517</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0032"><string-name><surname>Marston</surname><given-names>NA</given-names></string-name>, <string-name><surname>Giugliano</surname><given-names>RP</given-names></string-name>, <string-name><surname>Im</surname><given-names>K</given-names></string-name>, <string-name><surname>Silverman</surname><given-names>MG</given-names></string-name>, <string-name><surname>O'Donoghue</surname><given-names>ML</given-names></string-name>, <string-name><surname>Wiviott</surname><given-names>SD</given-names></string-name>, <string-name><surname>Ference</surname><given-names>BA</given-names></string-name>, <string-name><surname>Sabatine</surname><given-names>MS</given-names></string-name>. <article-title>Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid‐lowering therapeutic classes: a systematic review and meta‐regression analysis of randomized controlled trials</article-title>. <source>Circulation</source>. <year>2019</year>;<volume>140</volume>:<fpage>1308</fpage>–<lpage>1317</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.041998</pub-id>
<pub-id pub-id-type="pmid">31530008</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0033"><string-name><surname>Puri</surname><given-names>R</given-names></string-name>, <string-name><surname>Nissen</surname><given-names>SE</given-names></string-name>, <string-name><surname>Shao</surname><given-names>ME</given-names></string-name>, <string-name><surname>Puri</surname><given-names>R</given-names></string-name>, <string-name><surname>Nissen</surname><given-names>SE</given-names></string-name>, <string-name><surname>Shao</surname><given-names>M</given-names></string-name>, <string-name><surname>Elshazly</surname><given-names>MB</given-names></string-name>, <string-name><surname>Kataoka</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kapadia</surname><given-names>SR</given-names></string-name>, <string-name><surname>Tuzcu</surname><given-names>EM</given-names></string-name>, et al. <article-title>Non‐HDL cholesterol and triglycerides: implications for coronary atheroma progression and clinical events</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2016</year>;<volume>36</volume>:<fpage>2220</fpage>–<lpage>2228</lpage>. doi: <pub-id pub-id-type="doi">10.1161/ATVBAHA.116.307601</pub-id>
<pub-id pub-id-type="pmid">27515380</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0034"><string-name><surname>Grundy</surname><given-names>SM</given-names></string-name>, <string-name><surname>Stone</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Bailey</surname><given-names>AL</given-names></string-name>, <string-name><surname>Beam</surname><given-names>C</given-names></string-name>, <string-name><surname>Birtcher</surname><given-names>KK</given-names></string-name>, <string-name><surname>Blumenthal</surname><given-names>RS</given-names></string-name>, <string-name><surname>Braun</surname><given-names>LT</given-names></string-name>, <string-name><surname>de Ferranti</surname><given-names>S</given-names></string-name>, <string-name><surname>Faiella‐Tommasino</surname><given-names>J</given-names></string-name>, <string-name><surname>Forman</surname><given-names>DE</given-names></string-name>, et al. <article-title>2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/AphA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines</article-title>. <source>Circulation</source>. <year>2019</year>;<volume>139</volume>:<fpage>e1082</fpage>–<lpage>e1143</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIR.0000000000000624</pub-id>
<pub-id pub-id-type="pmid">30586774</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0035"><collab collab-type="authors">SPRINT Research Group</collab>
, <string-name><surname>Wright</surname><given-names>JT</given-names></string-name>, <string-name><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>Snyder</surname><given-names>JK</given-names></string-name>, <string-name><surname>Sink</surname><given-names>KM</given-names></string-name>, <string-name><surname>Rocco</surname><given-names>MV</given-names></string-name>, <string-name><surname>Reboussin</surname><given-names>DM</given-names></string-name>, <string-name><surname>Rahman</surname><given-names>M</given-names></string-name>, <string-name><surname>Oparil</surname><given-names>S</given-names></string-name>, et al. <article-title>A randomized trial of intensive versus standard blood‐pressure control</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>373</volume>:<fpage>2103</fpage>–<lpage>2116</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1511939</pub-id>
<pub-id pub-id-type="pmid">26551272</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0036"><string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name><surname>Carey</surname><given-names>RM</given-names></string-name>, <string-name><surname>Aronow</surname><given-names>WS</given-names></string-name>, <string-name><surname>Casey</surname><given-names>DE</given-names></string-name>, <string-name><surname>Collins</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Himmelfarb</surname><given-names>CD</given-names></string-name>, <string-name><surname>DePalma</surname><given-names>SM</given-names></string-name>, <string-name><surname>Gidding</surname><given-names>S</given-names></string-name>, <string-name><surname>Jamerson</surname><given-names>KA</given-names></string-name>, <string-name><surname>Jones</surname><given-names>DW</given-names></string-name>, et al. <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/AphA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines</article-title>. <source>Hypertension</source>. <year>2018</year>;<volume>71</volume>:<fpage>e13</fpage>–<lpage>e115</lpage>. doi: <pub-id pub-id-type="doi">10.1161/HYP.0000000000000065</pub-id>
<pub-id pub-id-type="pmid">29133356</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0037"><string-name><surname>Unger</surname><given-names>T</given-names></string-name>, <string-name><surname>Borghi</surname><given-names>C</given-names></string-name>, <string-name><surname>Charchar</surname><given-names>F</given-names></string-name>, <string-name><surname>Khan</surname><given-names>NA</given-names></string-name>, <string-name><surname>Poulter</surname><given-names>NR</given-names></string-name>, <string-name><surname>Prabhakaran</surname><given-names>D</given-names></string-name>, <string-name><surname>Ramirez</surname><given-names>A</given-names></string-name>, <string-name><surname>Schlaich</surname><given-names>M</given-names></string-name>, <string-name><surname>Stergiou</surname><given-names>GS</given-names></string-name>, <string-name><surname>Tomaszewski</surname><given-names>M</given-names></string-name>, et al. <article-title>2020 International Society of Hypertension global hypertension practice guidelines</article-title>. <source>Hypertension</source>. <year>2020</year>;<volume>75</volume>:<fpage>1334</fpage>–<lpage>1357</lpage>. doi: <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.15026</pub-id>
<pub-id pub-id-type="pmid">32370572</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0038"><string-name><surname>Cui</surname><given-names>Y</given-names></string-name>, <string-name><surname>Blumenthal</surname><given-names>RS</given-names></string-name>, <string-name><surname>Flaws</surname><given-names>JA</given-names></string-name>, <string-name><surname>Whiteman</surname><given-names>MK</given-names></string-name>, <string-name><surname>Langenberg</surname><given-names>P</given-names></string-name>, <string-name><surname>Bachorik</surname><given-names>PS</given-names></string-name>, <string-name><surname>Bush</surname><given-names>TL</given-names></string-name>. <article-title>Non‐high‐density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality</article-title>. <source>Arch Intern Med</source>. <year>2001</year>;<volume>161</volume>:<fpage>1413</fpage>–<lpage>1419</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archinte.161.11.1413</pub-id>
<pub-id pub-id-type="pmid">11386890</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0039"><string-name><surname>Ingelsson</surname><given-names>E</given-names></string-name>, <string-name><surname>Schaefer</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Contois</surname><given-names>JH</given-names></string-name>, <string-name><surname>McNamara</surname><given-names>JR</given-names></string-name>, <string-name><surname>Sullivan</surname><given-names>L</given-names></string-name>, <string-name><surname>Keyes</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Pencina</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Schoonmaker</surname><given-names>C</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>PWF</given-names></string-name>, <string-name><surname>D'Agostino</surname><given-names>RB</given-names></string-name>, et al. <article-title>Clinical utility of different lipid measures for prediction of coronary heart disease in men and women</article-title>. <source>JAMA</source>. <year>2007</year>;<volume>298</volume>:<fpage>776</fpage>–<lpage>785</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.298.7.776</pub-id>
<pub-id pub-id-type="pmid">17699011</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0040"><string-name><surname>Pischon</surname><given-names>T</given-names></string-name>, <string-name><surname>Girman</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Sacks</surname><given-names>FM</given-names></string-name>, <string-name><surname>Rifai</surname><given-names>N</given-names></string-name>, <string-name><surname>Stampfer</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Rimm</surname><given-names>EB</given-names></string-name>. <article-title>Non‐high‐density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>112</volume>:<fpage>3375</fpage>–<lpage>3383</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.532499</pub-id>
<pub-id pub-id-type="pmid">16316964</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0041"><string-name><surname>Shai</surname><given-names>I</given-names></string-name>, <string-name><surname>Rimm</surname><given-names>EB</given-names></string-name>, <string-name><surname>Hankinson</surname><given-names>SE</given-names></string-name>, <string-name><surname>Curhan</surname><given-names>G</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Rifai</surname><given-names>N</given-names></string-name>, <string-name><surname>Stampfer</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Ma</surname><given-names>J</given-names></string-name>. <article-title>Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>110</volume>:<fpage>2824</fpage>–<lpage>2830</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.CIR.0000146339.57154.9B</pub-id>
<pub-id pub-id-type="pmid">15492318</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0042"><collab collab-type="authors">Emerging Risk Factors Collaboration</collab>
, <string-name><surname>Di Angelantonio</surname><given-names>E</given-names></string-name>, <string-name><surname>Sarwar</surname><given-names>N</given-names></string-name>, <string-name><surname>Perry</surname><given-names>P</given-names></string-name>, <string-name><surname>Kaptoge</surname><given-names>S</given-names></string-name>, <string-name><surname>Ray</surname><given-names>KK</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>A</given-names></string-name>, <string-name><surname>Wood</surname><given-names>AM</given-names></string-name>, <string-name><surname>Lewington</surname><given-names>S</given-names></string-name>, <string-name><surname>Sattar</surname><given-names>N</given-names></string-name>, et al. <article-title>Major lipids, apolipoproteins, and risk of vascular disease</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>302</volume>:<fpage>1993</fpage>–<lpage>2000</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2009.1619</pub-id>
<pub-id pub-id-type="pmid">19903920</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0043"><string-name><surname>Madjid</surname><given-names>M</given-names></string-name>, <string-name><surname>Fatemi</surname><given-names>O</given-names></string-name>. <article-title>Components of the complete blood count as risk predictors for coronary heart disease: in‐depth review and update</article-title>. <source>Tex Heart Inst J</source>. <year>2013</year>;<volume>40</volume>:<fpage>17</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">23467296</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0044"><string-name><surname>Danesh</surname><given-names>J</given-names></string-name>, <string-name><surname>Wheeler</surname><given-names>JG</given-names></string-name>, <string-name><surname>Hirschfield</surname><given-names>GM</given-names></string-name>, <string-name><surname>Eda</surname><given-names>S</given-names></string-name>, <string-name><surname>Eiriksdottir</surname><given-names>G</given-names></string-name>, <string-name><surname>Rumley</surname><given-names>A</given-names></string-name>, <string-name><surname>Lowe</surname><given-names>GDO</given-names></string-name>, <string-name><surname>Pepys</surname><given-names>MB</given-names></string-name>, <string-name><surname>Gudnason</surname><given-names>V</given-names></string-name>. <article-title>C‐reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>350</volume>:<fpage>1387</fpage>–<lpage>1397</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa032804</pub-id>
<pub-id pub-id-type="pmid">15070788</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0045"><string-name><surname>Danesh</surname><given-names>J</given-names></string-name>, <string-name><surname>Collins</surname><given-names>R</given-names></string-name>, <string-name><surname>Appleby</surname><given-names>P</given-names></string-name>, <string-name><surname>Peto</surname><given-names>R</given-names></string-name>. <article-title>Association of fibrinogen, C‐reactive protein, albumin, or leukocyte count with coronary heart disease: meta‐analyses of prospective studies</article-title>. <source>JAMA</source>. <year>1998</year>;<volume>279</volume>:<fpage>1477</fpage>–<lpage>1482</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.279.18.1477</pub-id>
<pub-id pub-id-type="pmid">9600484</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0046"><string-name><surname>Hoffman</surname><given-names>M</given-names></string-name>, <string-name><surname>Blum</surname><given-names>A</given-names></string-name>, <string-name><surname>Baruch</surname><given-names>R</given-names></string-name>, <string-name><surname>Kaplan</surname><given-names>E</given-names></string-name>, <string-name><surname>Benjamin</surname><given-names>M</given-names></string-name>. <article-title>Leukocytes and coronary heart disease</article-title>. <source>Atherosclerosis</source>. <year>2004</year>;<volume>172</volume>:<fpage>1</fpage>–<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0021-9150(03)00164-3</pub-id>
<pub-id pub-id-type="pmid">14709350</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0047"><string-name><surname>Zahorec</surname><given-names>R</given-names></string-name>. <article-title>Neutrophil‐to‐lymphocyte ratio, past, present and future perspectives</article-title>. <source>Bratisl Lek Listy</source>. <year>2021</year>;<volume>122</volume>:<fpage>474</fpage>–<lpage>488</lpage>. doi: <pub-id pub-id-type="doi">10.4149/BLL_2021_078</pub-id>
<pub-id pub-id-type="pmid">34161115</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0048"><string-name><surname>Ikeda</surname><given-names>U</given-names></string-name>, <string-name><surname>Ikeda</surname><given-names>M</given-names></string-name>, <string-name><surname>Oohara</surname><given-names>T</given-names></string-name>, <string-name><surname>Kano</surname><given-names>S</given-names></string-name>, <string-name><surname>Yaginuma</surname><given-names>T</given-names></string-name>. <article-title>Mitogenic action of interleukin‐1α on vascular smooth muscle cells mediated by PDGF</article-title>. <source>Atherosclerosis</source>. <year>1990</year>;<volume>84</volume>:<fpage>183</fpage>–<lpage>188</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0021-9150(90)90089-2</pub-id>
<pub-id pub-id-type="pmid">2282097</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0049"><string-name><surname>Simpson</surname><given-names>E</given-names></string-name>, <string-name><surname>Cantor</surname><given-names>H</given-names></string-name>. <article-title>Regulation of the immune response by subclasses of T lymphocytes. II. The effect of adult thymectomy upon humoral and cellular responses in mice</article-title>. <source>Eur J Immunol</source>. <year>1975</year>;<volume>5</volume>:<fpage>337</fpage>–<lpage>343</lpage>. doi: <pub-id pub-id-type="doi">10.1002/eji.1830050509</pub-id>
<pub-id pub-id-type="pmid">1086235</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0050">
                <label>50</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0050"><string-name><surname>Targońska‐Stępniak</surname><given-names>B</given-names></string-name>, <string-name><surname>Zwolak</surname><given-names>R</given-names></string-name>, <string-name><surname>Piotrowski</surname><given-names>M</given-names></string-name>, <string-name><surname>Grzechnik</surname><given-names>K</given-names></string-name>, <string-name><surname>Majdan</surname><given-names>M</given-names></string-name>. <article-title>The relationship between hematological markers of systemic inflammation (neutrophil‐to‐lymphocyte, platelet‐to‐lymphocyte, lymphocyte‐to‐monocyte ratios) and ultrasound disease activity parameters in patients with rheumatoid arthritis</article-title>. <source>J Clin Med</source>. <year>2020</year>;<volume>9</volume>:<fpage>2760</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm9092760</pub-id><pub-id pub-id-type="pmid">32858869</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0051">
                <label>51</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0051"><string-name><surname>Malhotra</surname><given-names>R</given-names></string-name>, <string-name><surname>Marcelli</surname><given-names>D</given-names></string-name>, <string-name><surname>Von</surname><given-names>GG</given-names></string-name>, <string-name><surname>Grassmann</surname><given-names>A</given-names></string-name>, <string-name><surname>Schaller</surname><given-names>M</given-names></string-name>, <string-name><surname>Bayh</surname><given-names>I</given-names></string-name>, <string-name><surname>Scatizzi</surname><given-names>L</given-names></string-name>, <string-name><surname>Etter</surname><given-names>M</given-names></string-name>, <string-name><surname>Guinsburg</surname><given-names>A</given-names></string-name>, <string-name><surname>Barth</surname><given-names>C</given-names></string-name>, et al. <article-title>Relationship of neutrophil‐to‐lymphocyte ratio and serum albumin levels with C‐reactive protein in hemodialysis patients: results from 2 international cohort studies</article-title>. <source>Nephron</source>. <year>2015</year>;<volume>130</volume>:<fpage>263</fpage>–<lpage>270</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000437005</pub-id>
<pub-id pub-id-type="pmid">26182958</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0052">
                <label>52</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0052"><string-name><surname>de Jager</surname><given-names>CP</given-names></string-name>, <string-name><surname>van Wijk</surname><given-names>PT</given-names></string-name>, <string-name><surname>Mathoera</surname><given-names>RB</given-names></string-name>, <string-name><surname>de Jongh‐Leuvenink</surname><given-names>J</given-names></string-name>, <string-name><surname>van der Poll</surname><given-names>T</given-names></string-name>, <string-name><surname>Wever</surname><given-names>PC</given-names></string-name>. <article-title>Lymphocytopenia and neutrophil‐lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit</article-title>. <source>Crit Care</source>. <year>2010</year>;<volume>14</volume>:<fpage>R192</fpage>. doi: <pub-id pub-id-type="doi">10.1186/cc9309</pub-id><pub-id pub-id-type="pmid">21034463</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0053">
                <label>53</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0053"><string-name><surname>de Jager</surname><given-names>CP</given-names></string-name>, <string-name><surname>Wever</surname><given-names>PC</given-names></string-name>, <string-name><surname>Gemen</surname><given-names>EFA</given-names></string-name>, <string-name><surname>Kusters</surname><given-names>R</given-names></string-name>, <string-name><surname>Van</surname><given-names>G‐LAB</given-names></string-name>, <string-name><surname>Van Der Poll</surname><given-names>T</given-names></string-name>, <string-name><surname>Laheij</surname><given-names>RJF</given-names></string-name>. <article-title>The neutrophil‐lymphocyte count ratio in patients with community‐acquired pneumonia</article-title>. <source>PloS One</source>. <year>2012</year>;<volume>7</volume>:<elocation-id>e46561</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0046561</pub-id><pub-id pub-id-type="pmid">23049706</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0054">
                <label>54</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0054"><string-name><surname>Bhat</surname><given-names>T</given-names></string-name>, <string-name><surname>Teli</surname><given-names>S</given-names></string-name>, <string-name><surname>Rijal</surname><given-names>J</given-names></string-name>, <string-name><surname>Bhat</surname><given-names>H</given-names></string-name>, <string-name><surname>Raza</surname><given-names>M</given-names></string-name>, <string-name><surname>Khoueiry</surname><given-names>G</given-names></string-name>, <string-name><surname>Meghani</surname><given-names>M</given-names></string-name>, <string-name><surname>Akhtar</surname><given-names>M</given-names></string-name>, <string-name><surname>Costantino</surname><given-names>T</given-names></string-name>. <article-title>Neutrophil to lymphocyte ratio and cardiovascular diseases: a review</article-title>. <source>Expert Rev Cardiovasc Ther</source>. <year>2013</year>;<volume>11</volume>:<fpage>55</fpage>–<lpage>59</lpage>. doi: <pub-id pub-id-type="doi">10.1586/erc.12.159</pub-id>
<pub-id pub-id-type="pmid">23259445</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0055">
                <label>55</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0055"><string-name><surname>Angkananard</surname><given-names>T</given-names></string-name>, <string-name><surname>Anothaisintawee</surname><given-names>T</given-names></string-name>, <string-name><surname>McEvoy</surname><given-names>M</given-names></string-name>, <string-name><surname>Attia</surname><given-names>J</given-names></string-name>, <string-name><surname>Thakkinstian</surname><given-names>A</given-names></string-name>. <article-title>Neutrophil lymphocyte ratio and cardiovascular disease risk: a systematic review and meta‐analysis</article-title>. <source>Biomed Res Int</source>. <year>2018</year>;<volume>2018</volume>:<elocation-id>2703518</elocation-id>. doi: <pub-id pub-id-type="doi">10.1155/2018/2703518</pub-id><pub-id pub-id-type="pmid">30534554</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0056">
                <label>56</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0056"><string-name><surname>Fest</surname><given-names>J</given-names></string-name>, <string-name><surname>Ruiter</surname><given-names>TR</given-names></string-name>, <string-name><surname>Groot Koerkamp</surname><given-names>B</given-names></string-name>, <string-name><surname>Rizopoulos</surname><given-names>D</given-names></string-name>, <string-name><surname>Ikram</surname><given-names>MA</given-names></string-name>, <string-name><surname>van Eijck</surname><given-names>CHJ</given-names></string-name>, <string-name><surname>Stricker</surname><given-names>BH</given-names></string-name>. <article-title>The neutrophil‐to‐lymphocyte ratio is associated with mortality in the general population: the Rotterdam study</article-title>. <source>Eur J Epidemiol</source>. <year>2019</year>;<volume>34</volume>:<fpage>463</fpage>–<lpage>470</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10654-018-0472-y</pub-id>
<pub-id pub-id-type="pmid">30569368</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0057">
                <label>57</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0057"><string-name><surname>Gallo</surname><given-names>G</given-names></string-name>, <string-name><surname>Volpe</surname><given-names>M</given-names></string-name>, <string-name><surname>Savoia</surname><given-names>C</given-names></string-name>. <article-title>Endothelial dysfunction in hypertension: current concepts and clinical implications</article-title>. <source>Front Med</source>. <year>2022</year>;<volume>8</volume>:<elocation-id>798958</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fmed.2021.798958</pub-id></mixed-citation>
              </ref>
              <ref id="jah38796-bib-0058">
                <label>58</label>
                <mixed-citation publication-type="journal" id="jah38796-cit-0058"><string-name><surname>Ning</surname><given-names>B</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Waqar</surname><given-names>AB</given-names></string-name>, <string-name><surname>Yan</surname><given-names>H</given-names></string-name>, <string-name><surname>Shiomi</surname><given-names>M</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Chen</surname><given-names>YE</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Itabe</surname><given-names>H</given-names></string-name>, <string-name><surname>Liang</surname><given-names>J</given-names></string-name>, et al. <article-title>Hypertension enhances advanced atherosclerosis and induces cardiac death in Watanabe heritable hyperlipidemic rabbits</article-title>. <source>Am J Pathol</source>. <year>2018</year>;<volume>188</volume>:<fpage>2936</fpage>–<lpage>2947</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajpath.2018.08.007</pub-id>
<pub-id pub-id-type="pmid">30248339</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
